

Review

The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors



Lucie H. Clapp*, Rijan Gurung

Department of Medicine, UCL, Rayne Building, London WC1E 6JF, UK

ARTICLE INFO

Article history:

Available online 23 April 2015

Keywords:

Cell proliferation
 Pulmonary arterial hypertension
 Vascular remodelling
 Prostanoid receptors
 Peroxisome proliferator-activator receptor
 Prostacyclin analogues
 Cyclic AMP
 Treprostinil
 Iloprost
 Beraprost

ABSTRACT

Pulmonary arterial hypertension (PAH) is a progressive disease of distal pulmonary arteries in which patients suffer from elevated pulmonary arterial pressure, extensive vascular remodelling and right ventricular failure. To date prostacyclin (PGI₂) therapy remains the most efficacious treatment for PAH and is the only approved monotherapy to have a positive impact on long-term survival. A key thing to note is that improvement exceeds that predicted from vasodilator testing strongly suggesting that additional mechanisms contribute to the therapeutic benefit of prostacyclins in PAH. Given these agents have potent antiproliferative, anti-inflammatory and endothelial regenerating properties suggests therapeutic benefit might result from a slowing, stabilization or even some reversal of vascular remodelling in vivo. This review discusses evidence that the pharmacology of each prostacyclin (IP) receptor agonist so far developed is distinct, with non-IP receptor targets clearly contributing to the therapeutic and side effect profile of PGI₂ (EP₃), iloprost (EP₁), treprostinil (EP₂, DP₁) along with a family of nuclear receptors known as peroxisome proliferator-activated receptors (PPARs), to which PGI₂ and some analogues directly bind. These targets are functionally expressed to varying degrees in arteries, veins, platelets, fibroblasts and inflammatory cells and are likely to be involved in the biological actions of prostacyclins. Recently, a highly selective IP agonist, selexipag has been developed for PAH. This agent should prove useful in distinguishing IP from other prostanoid receptors or PPAR binding effects in human tissue. It remains to be determined whether selectivity for the IP receptor gives rise to a superior or inferior clinical benefit in PAH.

© 2015 Published by Elsevier Inc.

Contents

1. Introduction.....	57
2. Vascular wall remodeling in PAH.....	57
2.1. Rationale for PAH therapy: beyond just pulmonary vasodilatation.....	57
3. PGI ₂ , classical biological target and early clinical use.....	58
4. PGI ₂ analogues signal through multiple prostanoid receptors.....	59
5. PGI ₂ signalling through nuclear receptors.....	61
5.1. Vascular protective effects of PPARs.....	62
5.2. IP receptor and PPARs as regulators of cell proliferation.....	62
6. Impact of pulmonary hypertension on PGI ₂ signalling.....	64
7. Role of PPARs in lung remodelling in the context of PAH.....	65
8. Anti-inflammatory actions of prostacyclins.....	66
9. Concluding remarks.....	67
Disclosures.....	67
References.....	67

* Corresponding author at: BHF Laboratories, Department of Medicine, UCL, Rayne Building, 5 University Street, London WC1E 6JF, UK. Tel.: +44 207 6796180.
 E-mail address: l.clapp@ucl.ac.uk (L.H. Clapp).

1. Introduction

Pulmonary arterial hypertension (PAH) is a debilitating and fatal disease, involving extensive remodelling and narrowing of the blood vessels within the pulmonary vasculature. This leads to increased pulmonary vascular resistance and right ventricular hypertrophy, with eventual heart failure and death [1]. Without appropriate treatment, adults with PAH have a median life expectancy of 2.8 years from diagnosis while children have less than 10 months [2,3]. The disease is probably initiated by endothelial damage, caused by a combination of sheer stress, hypoxia and genetic factors (including mutations in the transforming growth factor family of genes), leading to increased production of vasoconstrictors (endothelin and thromboxane) accompanying the loss of vasodilator and anti-platelet agents, prostacyclin (PGI₂) and nitric oxide (NO). This process is exacerbated by ion channel dysfunction, including loss of potassium channel activity/expression (voltage-gated and the two-pore domain K⁺ channels) and upregulation of calcium entry through canonical transient receptor potential cation (TRPC) channels both of which will lead to smooth muscle membrane depolarisation and Ca²⁺ influx [4]. The earliest known pathology in PAH is medial thickening due to hypertrophy and hyperplasia. However, as the disease progresses, proliferation of adventitial and intimal layers take over and uncontrolled endothelial proliferation is thought to underlie plexiform lesions. High cell proliferation rates within all layers (adventitia, media and endothelium) coupled with decreased programmed cell death (apoptosis) is a widely accepted explanation for the structural changes seen in PAH [1,5–7]. Indeed proliferative rates of human pulmonary arterial smooth muscle cells (PASMCs) isolated from patients with idiopathic PAH (IPAH) and grown in culture are close to double that of normal cells, suggesting a switch from a less contractile to a more proliferative cellular phenotype [8,9]. Moreover proliferative rates are much higher in paediatric versus adult IPAH cells, consistent with the particularly aggressive nature of this disease in children [9]. In addition, PASMCs isolated from PAH patients lose responsiveness to bone morphogenetic protein (BMP) ligands and display excessive proliferation in response to transforming growth factor β1 (TGF-β1), when typically both these agents have antiproliferative and apoptotic effects in normal cells [10,11]. Thus, the disease appears to alter the intrinsic properties either of resident smooth muscle cells, or those cells which have become incorporated into the hyperplastic medial layer. One such event which may drive this is sustained hypoxia, which can cause the recruitment of cells with enhanced growth, migratory and pro-mitogenic features in the wall of distal pulmonary arteries [12]. Factors that appear to drive these phenotypic changes, include platelet-derived growth factor (PDGF), and other mitogens such as the chemokine stromal cell derived factor, SDF-1/CXCL12 as well as the calcium binding protein and a mediator of metastasis, S100A4 [12].

2. Vascular wall remodeling in PAH

The aggressive pulmonary vascular obliterative disease characteristic of PAH, as already mentioned, involves all cell types within the vessel wall. Smooth muscle cells are initially hyperplastic and hypertrophied, and then become atrophied as fibrotic intimal proliferation develops. Adventitial fibroblasts proliferate and migrate. Endothelial damage is marked and plexiform lesions are thought to consist of proliferating abnormal endothelial cells which may sometimes consist of monoclonal endothelial cell expansion [6,13]. Thus, it comes as no surprise that patients with PAH have elevated levels of several growth factors, including PDGF, vascular endothelial growth factor (VEGF), TGF-β, epidermal growth factor

(EGF), fibroblast growth factor (FGF) and angiopoietin [6,7,14,15]. A number of proproliferative signalling pathways involving growth factors, cytokines, metabolic signalling, and elastases and proteases have been identified in the pathophysiology of PAH. These combine to induce proliferation and migration of smooth muscle, endothelial cells and fibroblasts, while VEGF and angiopoietin (1 and 2) are also key markers of angiogenic remodelling. Metalloproteinases (MMPs) which are also elevated in PAH [15] and other inflammatory lung diseases [16] contribute to structural remodeling by growth factor activation, degradation of extracellular matrix proteins (collagens, gelatins and proteoglycans) and disruption of the internal elastic lamina [6]. Inflammation is also a key component of PAH, with thrombotic lesions and infiltration of T-cells, monocytes, macrophages, dendritic and mast cells into other types of lesions, commonly observed [7,14]. While traditionally inflammation is thought to center around the recruitment of inflammatory cells to the intima of blood vessels, driven by the expression of adhesion molecules on the endothelium (see later), increasing evidence suggest that inflammation may be initiated and/or driven from within the perivascular and adventitial layers – the so called “inside out hypothesis”. Here adventitial fibroblasts play a key role in providing the environment in which leukocytes can rapidly infiltrate and recruit monocytes and progenitor cells to the site of vascular injury, where they produce many factors driving the expression of adhesion molecules, growth factors, cytokines and chemokines [7]. Of note, the adventitial layer was reported to undergo the highest expansion in arteries between 50 and 100 μm in IPAH patients, with increased collagen deposition being the major cause of this increase in thickness [17]. The extent to which venous remodelling contributes to the pathology in IPAH is currently a subject of much debate [7], and is thwarted by the difficulty in identifying veins that might masquerade as a remodelled artery, and for which there is no consistent cellular biomarker. That said, in a systematic study of veins identified as vessels having a single elastic lamina, a doubling of intimal and adventitial layers was documented, but reported to result from collagen deposition rather than cell proliferation [17]. Evidence of chronic inflammation with resident monocytes and intra alveolar macrophages was also seen in 65% of patients. Thus, structural changes in the venous circulation probably contribute to disease pathology in PAH.

2.1. Rationale for PAH therapy: beyond just pulmonary vasodilatation

The rationale behind the treatment of PAH is to lower pulmonary arterial pressure (PAP) and hence bring about a reduction in pulmonary vascular resistance (PVR) and right heart afterload [1]. Thus, it is not surprising that therapies based around promoting vasodilatation have been developed, and include PGI₂ (epoprostenol) or stable analogues, endothelin-1 (ET-1) receptor antagonists (ERAs) as well as cyclic GMP (cGMP) elevating agents that combine to increase NO bioavailability by either inhibiting phosphodiesterase type five (PDE5) (sildenafil, tadalafil) and preventing the breakdown of cGMP or by stimulating guanylyl cyclase (riociguat) [18,19]. Randomized controlled trials have described improvements in pulmonary hemodynamics, exercise tolerance and clinical symptoms with each class of agents, though to date the only monotherapy demonstrating a significant impact on long-term survival (3–5 years) in controlled clinical trials is PGI₂, where survival at 3 and 5 years was 63% and 55%, respectively in PAH patients [1]. In open labeled or retrospective long-term analysis of subcutaneous (SC) treprostinil, patterns of observed survival versus predicted appear to be similar or possibly slightly better (69% at 3 years) than those seen with IV epoprostenol involving patients with similar baseline characteristics [20–24]. In the latter study, this occurred despite a high proportion (44%) of

patients in WHO functional class IV. Moreover, in the same study outcomes were beyond expectations in a group of patients who could tolerate up-titration of treprostinil beyond 6 months, with survival being 57% at 9 years, though overall the rate in the whole patient group at this time was 35% [24]. Comparisons with iloprost are difficult to make, given the most common formulation of this drug is inhalation. Where data exists, event free survival rates are poor (20% at 3 years) though a 59% survival rate was recorded at 3 years [25] accepting 20% of patients were on an additional therapy. It should be noted that transition from inhalation to IV late on in the disease was reported not to improve outcome [26]. In the only long-term randomized controlled trial of beraprost, this agent improved exercise capacity with evidence of less disease progression at 6 months, though such beneficial effects were not present at >9 months [27]. Taken together, differences in the efficacy and survival rates within the PGI₂ class of drugs may reflect either their distinct pharmacology [28–30] and/or their differential ability to inhibit human pulmonary artery smooth muscle cell (PASMC) proliferation [31]. To this end it is worth noting that the rank order of PGI₂ analogues to inhibit normal human PASMC proliferation was treprostinil (UT-15) > iloprost > beraprost [31], thus at least matching clinical observations about long-term efficacy.

Despite the wide use of vasodilator therapy in PAH, pulmonary vasodilation does not necessarily predict either a fall in PVR or a positive benefit, nor is it consistently observed beyond the first 3–4 few months of therapy [32]. Indeed <15% of PAH patients are responsive to any type of vasodilator therapy at all, and of those, only ~6% respond to long-term oral calcium channel blocker therapy [33]. Likewise, significant clinical improvement exceeding that predicted from vasodilator testing alone is widely documented [1,18,34,35]. Taken together, this strongly suggests the long-term benefits of PGI₂ and its stable analogues in PAH are related to other biological properties of these agents, and probably results from their known anti-proliferative and anti-inflammatory properties in many cell types [36,37]. This has led to the widely held view that prostacyclins slow or may even reverse the vascular remodelling process in PAH, as clearly demonstrated in experimental models, even when iloprost or treprostinil are administered after the establishment of PAH [38,39]. Indeed all 3 main class of agents used to treat PAH are expected to promote inhibition of vascular smooth muscle cell growth [40,41] with antiproliferative effects of prostacyclins, cGMP elevating agents and ERAs recognised as an important property of these agents in ACCF/AHA 2009 Expert Consensus Document on PH [1]. Few studies have however attempted to compare relevant biological readouts of current treatments. When we compared the antiproliferative properties of clinically approved therapies under the same experimental conditions, the lowest dose to significantly inhibit ET-1 induced cell growth in PASMCs derived from PAH patients, varied 10,000-fold (0.1 nM to 1 μM) with a rank order being treprostinil > riociguat ≥ selexipag metabolite ≥ tadalafil = iloprost ≫ macitentan ≥ bosentan [42]. Thus PGI₂ mimetics and cGMP elevating agents appear substantially more effective as antiproliferative agents than mixed (ET_A and ET_B) ERAs. This is a somewhat surprising result, given that ET-1 contributes to enhanced proliferation in PAH through increased smooth muscle receptor expression [5,43], but may reflect the fact that ET-1 binds with high affinity to ET_A and ET_B receptors with a half-life of dissociation lasting hours, making them a challenge to antagonise pharmacologically [44]. That PGI₂ and cGMP elevating agents are effective as anti-proliferative, suggests these agents can either act downstream of ET-1 receptors and/or inhibit ET-1 synthesis, as has been documented for both prostacyclins and cGMP elevating agents [5,45,46]. Thus cAMP and cGMP elevating agents given alone or in combination may be a good strategy in those patients who have high ET-1, levels of which predicts a poor survival outcome in PAH.

These results therefore predict a hugely variable response on cell proliferation for current therapies.

The remainder of this article will focus on the recent advances in our understanding of the mechanistic basis for PGI₂ effects on smooth muscle cell proliferation and vascular remodeling through classical (membrane IP receptors) and non-classical (nuclear receptors) pathways. In addition, we will discuss the implications arising from the key differences in the pharmacological action of PGI₂ agonists which may have an impact on their therapeutic targets and/or give rise to agents with different efficacies and side-effect profiles. The evidence that prostacyclins have potent anti-inflammatory properties with the ability to also promote endothelial repair and regeneration, will also be discussed.

3. PGI₂, classical biological target and early clinical use

PGI₂ is a 20 carbon prostanoid derivative formed within vascular endothelial and smooth muscle cells in response to the oxidation of arachidonic acid by cyclooxygenase (COX-1 and COX-2) enzymes [47]. Back in late 1970s, John Vane and co-workers reported that arteries (but not platelets) contained an enzyme (PGI₂ synthase; PGI₂S) which transformed prostaglandin intermediates to an unstable substance (PGI₂) that inhibited platelet aggregation in a cyclic AMP-dependent manner (reviewed in Refs. [47,48]). The nature of the receptor pathway was confirmed two decades later when, in 1994, the seven-transmembrane PGI₂ (IP) receptor from human, mouse and rat was cloned and expressed in cells by Narumiya and colleagues (see [49] for details). Activation of this plasma membrane receptor is coupled via Gs to adenylyl cyclase and cyclic AMP (cAMP) generation [49]. Once elevated, cAMP is rapidly broken down by specific phosphodiesterases (PDE), with PDE 1, 3, 4 largely responsible for regulating basal levels and analogue-induced elevation in the lung [50–52]. Experiments in IP receptor knockout mice confirmed that the anti-aggregatory and blood pressure lowering properties of the PGI₂ analogue, cicaprost was indeed through this receptor [53] as were the majority of its antiproliferative effects in cultured mouse PASMCs [9].

Not long after the discovery of PGI₂, this agent (epoprostenol) was given to patients with PAH and shown to be a potent dilator in both the systemic and pulmonary circulation [54], including in a subset of severely diseased patients not responding to traditional oral vasodilator therapy at all [55]. At the time of these small scale studies, much of the focus of PGI₂ in the clinical arena was for the treatment of peripheral vascular disease such as critical limb ischemia associated with atherosclerosis and Buerger's disease [56]. Mechanistic studies in the late 1980s suggested that PGI₂ was a potent inhibitor of growth factor release from platelets and leukocytes, in particular PDGF, a key driver of smooth muscle cell proliferation and neointimal formation in atherosclerosis [57]. This coupled with the lipid lowering and anti-proliferative effects of PGI₂ in cultured aortic cells from a number of species, including human, were all evidence for the anti-atherosclerotic potential of PGI₂ (reviewed in Ref. [57]). Subsequently, the importance of PGI₂ in this disease process has been further highlighted in gene transfer and deletion experiments. Thus overexpression of PGI₂S inhibited neointimal formation in animal models of arterial injury [58,59] and vascular smooth muscle cell proliferation induced by serum [60]. In contrast, deletion of the synthase in mice resulted in raised blood pressure, fibrosis and the development of vascular disorders with thickening of vascular walls in the kidney but also in the aorta with age [61]. Likewise, in IP receptor knockout mice, greater platelet activation and vascular smooth muscle cell proliferation in response to vascular injury were observed as well as enhanced atherogenesis when either the low density lipid (LDL)-receptor or apolipoprotein-E (apoE) gene was knocked out together with the IP

receptor [62,63]. Loss of the IP receptor, while not affecting blood pressure, does lead to an exaggerated hypertensive and remodeling effect of hypoxia in the lung [64], as well as an augmented cardiac hypertrophy in response to pressure overload [53,64,65] and mice develop salt-sensitive hypertension [66]. Furthermore, the potent angiogenic and anti-remodelling effects of bone-marrow derived endothelial progenitor cells (EPCs) in both a hind limb ischemia and vascular injury model were impaired in IP^{-/-} null mice [67,68]. The mechanism may in part be due to a reduction in adhesion of EPCs to the relevant sites of repair [68].

Thus, there is strong evidence that PGI₂, through activation of its classical biological target, the IP receptor, is protective in the context of proliferative diseases such as atherosclerosis and PAH.

4. PGI₂ analogues signal through multiple prostanoid receptors

Prostacyclin is clinically hard to work with because it is chemically unstable with a half-life either *in vitro* or *in vivo* of approximately 3 min at a physiological pH and temperature [69]. Given this inherent instability, chemists set about making a series of compounds based around PGI₂ that were not susceptible to hydrolysis in solution and had a longer biological half-life. Iloprost, which shares the same pentanoic side chain to PGI₂, will however very slowly degrade at room temperature and is most susceptible to β-oxidation making its terminal plasma half-life less (20–30 min) than either beraprost (40–60 min) or treprostinil (180–270 min) [70–72]. Several drug formulations now exist for clinical use including intravenous (iloprost, treprostinil), oral (beraprost, treprostinil), inhaled (iloprost and treprostinil) and subcutaneous (treprostinil). As shown in Table 1, like PGI₂, all stable PGI₂ analogues potentially bind to the IP receptor. Iloprost is approximately 10-fold more potent than treprostinil [29], consistent with the observed potency difference of these two agents to inhibit IP-dependent relaxation in human pulmonary artery [73]. Selexipag (NS-304) is a novel non-prostanoid moiety that is currently being developed as an oral drug for PAH [74], with Phase III trials (GRIPHON) now complete. It differs from other PGI₂ analogues in that selexipag is a pro-drug with a relatively low affinity at the IP receptor (K_i 260 nM), but is rapidly hydrolyzed *in vivo* to the active metabolite, MRE-269 (ACT-333679), which has a high affinity for the human IP receptor (K_i 20 nM) and a long (~8 h) plasma half-life [75,76]. Despite the selexipag metabolite having a high IP receptor potency, it like PGI₂, was comparatively weak at relaxing human pulmonary artery, with its concentration-response curve shifted by two orders of magnitude to the right compared to iloprost [73]. The reason for this discrepancy is not immediately obvious considering that neither selexipag nor its metabolite have significant binding affinity ($K_i \geq 2.6 \mu\text{M}$) for any other prostanoid receptor that might oppose its action at the IP receptor, but might be explained on the basis of multiple targets for the other analogues (see below). In other experiments where IP agonists have been compared as antiproliferative agents under the same experimental conditions, effects of iloprost and MRE-269 were broadly similar, whereas treprostinil was an order of magnitude more effective [42], as observed previously when analogues were compared in normal human PSMCs [31].

Increasing evidence suggest that prostacyclins have significant actions at other prostaglandin receptors which might contribute to or modulate their therapeutic action (Table 1 and Fig. 1). The EP₂, EP₄ and DP₁ receptors are vasorelaxant receptors coupled to Gs and therefore elevate intracellular cAMP levels while EP₁, EP₃, FP and TP are contractile receptors coupled to Gi and Gq that either elevate intracellular Ca²⁺ and/or reduce cAMP [77]. Although difficult to assess in binding studies, PGI₂ is known to have poor selectivity

for prostanoid receptors, binding to and activating EP₁, EP₃ and TP receptors, albeit at higher concentrations (15–45-fold for EP₁ and EP₃ and <100-fold for TP) compared with the corresponding natural ligand [78–80]. This still means that such receptors will be significantly activated by PGI₂ between 10 and 40 nM (EP₃) and ~100 nM (EP₁ and TP), with the plasma concentration of epoprostenol (as measured by its metabolite, 6-keto-prostaglandin F_{1α}) estimated to be ~25 nM in PAH patients [81]. Activation of these receptors would therefore lead to vasoconstriction, thrombosis and cell proliferation [49,82]. In human lung and platelets, EP₃ and TP receptors are the main prostanoid receptors to oppose signalling through IP receptors, the exception being pulmonary veins where EP₁ and TP receptors appear to counteract prostanoid-induced relaxation [82,83]. Thus, PGI₂ has the potential for deleterious effects if IP receptor expression is compromised and/or if TP/EP receptor signaling is enhanced. Indeed, in mice genetically deficient of the IP receptor, vascular proliferation and platelet activation are increased in response to tissue injury whereas the opposite occurs in TP receptor knockout mice [84]. Moreover, thromboxane levels rise in response to injury when the IP receptor gene is deleted and the vasodilator response to cicaprost is converted to vasoconstriction [84], the latter presumed to relate to activation of the EP₃ receptor which is negatively coupled to adenylyl cyclase via Gi [85,86]. Taken together, this suggests that the balance between these receptor pathways is crucial in maintaining vascular homeostasis. The PGI₂ and thromboxane pathways are intrinsically linked at the receptor level since the TP receptor can dimerise with the IP receptor in native cells, where TP agonists behave in an “IP-like” manner and actually increase intracellular cAMP. Such an association, serving to limit the deleterious effects of thromboxane, was reported recently to be disrupted under conditions of hypercholesterolemia [87]. Given that IP but not TP homodimer function was shown in the same study to be down-regulated, suggests that atherosclerotic disease preferentially enhances TP receptor signalling. This may in part explain why, ApoE null mice fed a high cholesterol diet, might develop PAH [88] (Fig. 2).

Like PGI₂, iloprost has poor selectivity for prostanoid receptors, being essentially equipotent at activating both IP and EP₁ receptors [49,89], and this was recently confirmed ([29] and Table 1). Thus it is not surprising that iloprost-induced vasorelaxation can be enhanced by EP₁ receptor blockade in isolated rabbit perfused lungs [52] or in guinea-pig aorta [90]. The significance of EP₁ receptor activation is not widely understood, but its activation may contribute to loss of efficacy clinically in PAH, either through enhanced IP receptor desensitisation [52] or reduced cAMP generation through activation of the calcium/calmodulin-dependent PDE1 isoform [91]. Functional EP₁ receptors are found in the gastrointestinal track, causing contraction of the human colon, while in the stomach, these receptors can have either detrimental or beneficial effects, worsening histamine-induced gastric injury and delaying gastric emptying while providing cytoprotection against acid- and ethanol-induced injury of the mucosa [77,92].

Iloprost has been reported to have significant activity at the human EP₄ receptor, though not at the mouse receptor (Table 1). Despite notable expression of EP₄ receptors in the human lung [93], they do not appear to mediate relaxation of human pulmonary arteries but may in veins [82,83], though relaxations induced by iloprost (and treprostinil) were recently found to be insensitive to EP₄ antagonists in both arteries or veins [73]. In situations where the IP receptor is down regulated (in PAH or high cell passage number), it is possible that EP₄ receptors may generate sufficient cAMP for a functional response on vascular tone or cell proliferation [93]. However, this would appear to occur at concentrations well outside (>50-fold) the therapeutic dose range [29,89], with the upper plasma concentration achieved in patients with this drug being close to 1 nM [94]. This strongly suggests that EP₄

Table 1
Distinct differences in prostanoid receptor binding affinities (K_i) for prostacyclin (PGI₂) mimetics compared with PGI₂, prostaglandin E₂ (PGE₂) and prostaglandin D₂ (PGD₂) at human and mouse (rat) prostanoid receptors. Radioligand binding data (K_i in nM) are from original study references for PGI₂ analogues, PGE₂, PGD₂ and for selexipag and its metabolite [29,75,89,224]. K_i values for PGI₂ against IP and EP₄ receptors come from three individual studies where [³H]-PGI₂ showed saturable binding at a single high affinity site or displaced [³H]-PGE₂ [225–227]. Estimated K_i values for EP₁, EP₃, and TP receptors come from historical dose-ratio and binding data where PGI₂ contractile effects have been directly with PGE₂ [78–80]. Blank means K_i value >3 μM, ND means not done, YES indicates evidence for functional activity and NO means the opposite.

Ligands		IP	DP	EP1	EP2	EP3	EP4	TP	FP
Cicaprost	Human	17	>1340	>1340	>1340	255	44	>1340	>1340
	Mouse	10		1300		170			
Iloprost	Human	4	1016	1	1172	203 (56) ^a	212		131
	Mouse	11		21	1600	27	2300		
Beraprost	Human	39				680			
	Mouse (rat)	16 (19)				110			
Treprostinil	Human	32	4.4	212	3.6	2505	826		
	Mouse	YES	ND	ND	YES	ND	ND	ND	ND
Selexipag	Human	260							
	Rat	2100							
MRE-269	Human	20	2600						
	Rat	220							
PGI ₂	Human	2	ND	≥100	ND	10–40		~100	ND
	Mouse (GP)	17 (16)	ND	~200	ND	12–50	NO	~100	ND
PGE ₂	Human		307	9.1	4.9	0.3	0.8		119
	Mouse			20	12	0.8	1.9		100
PGD ₂	Human		2		2973	421	1483		7
	Mouse		21			280			47

^a K_i value from Ref. [89] and GP = guinea-pig.

receptors are not likely to be a clinically relevant target for iloprost.

Until recently, little was known about the pharmacology of treprostinil, though enhanced and more prolonged cAMP generation compared to other analogues was originally reported in both human PSMCs and mouse alveolar macrophages, strongly suggesting signalling through additional Gs coupled receptors [31,95]. This was largely accounted for in macrophages by activation of EP₂

but not EP₄ receptors [95]. In comparative binding studies, treprostinil, in contrast to iloprost, was shown to have high affinity for the DP₁ and EP₂ receptor (K_i 4.4 and 3.6 nM, respectively) while having a 100-fold lower affinity for EP₁ ([29] and Table 1). A similar pattern was observed for functional assays (cAMP and calcium) in the same study, confirming the unique pharmacology of treprostinil with respect to iloprost and other PGI₂ analogues [89]. Consistent with these findings, treprostinil was a more potent vasodilator of




Fig. 1. Prostacyclin (PGI₂) drugs differentially bind to multiple prostanoid receptors at therapeutic doses. All PGI₂ mimetics, including selexipag and its metabolite, bind to the IP receptor which is coupled via Gs to adenylyl cyclase and cyclic AMP production. PGI₂ can also bind to and activate the EP₃ receptors in human pulmonary arteries and platelets and gut (not shown). These receptors counteract IP receptor signalling by lowering cyclic AMP levels through Gi. Iloprost can bind with equipotent affinity to the EP₁ receptor, which elevates intracellular Ca²⁺ through activation of Gq, and an unknown G-protein pathway; the consequence would be to cause vasoconstriction and cell proliferation as well as produce functional effects in the gut as indicated. Treprostinil has 10-fold higher affinity at EP₂ and DP₁ receptors compared to the IP receptor, activation of which will also elevate cAMP. Both these receptors are found in airways, platelets and fibroblasts, and EP₂ receptors along with IP receptors, are expressed in various inflammatory cell types where they reduce inflammation (not shown). AC, adenylyl cyclase; cAMP, cyclic adenosine monophosphate; DAG, diacylglycerol; G, G protein; IP₃, inositol triphosphate; PKA, protein kinase A; PLC, phospholipase C; PIP₂, phosphatidylinositol 4,5-bisphosphate.

human pulmonary veins than arteries and DP₁ receptor activation could account for this, whereas PGI₂ was a poor venorelaxant, while iloprost was equipotent [73]. Moreover, when treprostinil was assessed as a vasorelaxant in several isolated smooth muscle preparations, it was equipotent with PGE₂ against EP₂ receptors (EC₅₀ 4–5 nM) in mouse trachea and only 3–4 times less potent than PGD₂ at DP₁ receptors in rabbit saphenous vein and vena cava [96]. Thus in functional assays, treprostinil is behaving like potent EP₂ and DP₁ agonist. Given the plasma concentration achieved with intravenous or subcutaneous treprostinil in patients ranges between 2.5 and 25 nM [97], strongly suggests EP₂ and DP₁ receptors will be activated within the therapeutic window of this drug. Thus activation of IP, DP₁ and EP₂ receptors, all of which are linked to cAMP generation could act in concert to produce the biological effects of treprostinil.

One consequence of having an agent that can potentially relax veins might be to prevent pulmonary oedema, commonly caused by vasoconstriction or loss of vein distensibility by collagen deposition [98]. Both endothelin and thromboxane constrict human veins more potently than arteries and increase microvascular pressure, suggesting when their levels are high, this will increase the risk of oedema in PAH (see Ref. [98] for discussion). PGI₂ has detrimental effects in patients with pulmonary veno-occlusive disease (POVD), presumably because it will cause pooling of the blood in the veins due to a mismatch of arterial and venous blood flow, whereas this is not likely to happen with iloprost and treprostinil [73]. Thus, one might argue in favour of either agent, particularly treprostinil, being considered in post-capillary disease, where venous remodelling due to high pressure is a major problem.

Another prediction from the pharmacology of treprostinil is that it will be a particularly effective bronchial dilator and inhibitor of platelet function as human bronchial smooth muscle [99,100] and platelets [101,102] both express functional IP, DP₁ and EP₂ receptors. Indeed treprostinil was reported to inhibit human platelet aggregation with an EC₅₀ in the subnanomolar range [103]. EP₂ receptors have other important functions to consider in the context of a fibrotic disease like PAH. These receptors significantly contribute to the antiproliferative effects of PGE₂ in cultured human airway smooth muscle and fibroblasts [104,105]. The role of EP₂ receptor in the context of remodelling in PAH is unknown, though neointimal hyperplasia in response to injury was accelerated in EP₂^{-/-} mice, and associated with increased proliferation and migration of smooth muscle cells [106]. It is also important to note that activation of EP₂ receptors has a range of inhibitory effects on fibroblast function (proliferation, migration, transition from fibroblast to myofibroblast) that is driven largely by PDGF and TGFβ, which could therefore contribute to the beneficial effects of treprostinil in PAH [107–109].

Other potential targets for PGI₂ and its analogues include EP₃ receptors [89] which may negatively modulate vasorelaxation induced by analogues [76,86,110], particularly in small pulmonary vessels where EP₃ agonists are more effective vasoconstrictor agents [110]. Extrapolation from historical dose-ratios comparing the functional effects of prostaglandin E₂ and PGI₂ with the binding data in Table 1, would make PGI₂ the only prostacyclin drug to potentially activate EP₃ receptors in the clinical dose-range. Indeed, in the rat fundus potent (EC₅₀ 53 nM) contractile effects are reported for PGI₂ [80], with double that required to elicit contractions with iloprost in the same preparation and even higher (1 and 10 μM) for beraprost and treprostinil, respectively [111]. The situation may differ under conditions when IP receptors are down regulated, as occurs in PAH [9,93]. Furthermore, contractile agents, particularly phenylephrine, can markedly potentiate the effects of EP₃ agonists, where strong contractions are only observed with some 'priming' beforehand [112] a situation which makes PGI₂ activate TP receptors in the sub nanomolar range and contract rat

pulmonary arteries further [113]. This may be relevant under conditions of high sympathetic tone coupled to high thromboxane levels, as is likely to occur in PAH.

5. PGI₂ signalling through nuclear receptors

Apart from clear differences in the functional consequence of gene deletion of the IP receptor and PGI₂S, it has been acknowledged for a while that IP receptors alone cannot fully account for the known biological actions of PGI₂. Since the discovery that PGI₂S has a bimodal distribution in vascular smooth muscle cells, showing strong expression in both plasma membrane and perinuclear regions [114], the importance of PGI₂ signalling through a family of transcription factors called peroxisome proliferator-activated receptors (PPARs) has now been widely recognised [115,116]. PPARs are generally activated by ligand binding and contain a central DNA-binding domain that recognises response elements in the promoters of their target genes. Three main isoforms exist, PPARα, PPARβ/(δ) and PPARγ, and in the mid to late 1990s were shown to be activated by a variety of endogenous ligands, including prostaglandins (e.g. prostaglandin A₁, A₂, B₂, D₂, 15-Deoxy-Δ^{12,14}-PGJ₂), fatty acids (e.g. linoleic), and lipoxygenase metabolites (e.g. 8-HETE) as well as by a variety of synthetic agents [117,118]. At the time of these experiments, it was noted that the PGI₂ analogues, iloprost and carbacyclin could directly bind to PPAR α or β and activate them as efficiently as endogenous and synthetic ligands [118]. This was not a property shared by cicaprost, and for that matter PGI₂, though with the latter, this was presumed to be due to its rapid hydrolysis under experimental conditions [118]. Using crystal structures of the ligand binding domain, the structural basis for iloprost binding to PPAR α and β has now unequivocally been confirmed, though interestingly direct binding to PPARγ with iloprost could not be demonstrated [119]. This distinctive property of iloprost and of other analogues, including beraprost [120] and treprostinil [103], has often been used to distinguish between signalling through the IP receptor and PPARs. There are a number of instances where the angiogenic, anti-tumour or antiproliferative effects attributed to PGI₂ or analogue activation of PPARs is either not mimicked by cicaprost and/or does not involve IP receptors [9,121–123]. Nonetheless, there are circumstances where PPAR activation can be driven by the IP receptor and/or be seen with cicaprost [124,125], suggesting cross talk between PPARs and IP receptors does actually occur. Indeed cAMP-dependent protein kinase A (PKA) is known to phosphorylate and activate the ligand binding domain of PPARs [126]. However, IP receptor-dependent activation of PPARγ, while involving phosphorylation of the ligand binding domain, was found to be independent of cAMP generation and PKA [125]. Given that many other kinases can regulate PPAR activity, including GMP-dependent kinase both in the absence and presence of ligands [127,128] suggests complex regulation by other receptors and/or signalling pathways.

Thus, signalling through PPARs represents an important biological target for prostacyclins. Indeed, neither the IP receptor nor cAMP appears to be involved in mediating iloprost relaxation in some rodent blood vessels [30,129] possibly suggesting a major role for PPARs. However, a lot more work is required to tease out the specific role of membrane receptor activation versus direct analogue binding, the cross talk between the two, as well as signalling through endogenously produced eicosanoids, which so far has largely been ignored. The possibility that both membrane and nuclear signalling are required to be inhibited before the role of either pathway can be confirmed should also be considered (c.f. [96]).

The cellular function of PPARs is diverse, regulating processes such as lipid and glucose metabolism, insulin sensitivity, cell growth, apoptosis and inflammation [115,127,130]. Synthetic and

highly selective activators exist for each of the PPAR isoforms and these have been extremely useful in identifying the physiological and pathophysiological function of these transcription factors in different cell types. Fibrates activate PPAR α and are used clinically in the treatment of hyperlipidaemia while glitazones activate PPAR γ and are used to treat type-2 diabetes [127]. GW501516 and GW0742 are highly selective activators of PPAR β and their development has mostly been directed towards treatment of metabolic syndromes [116].

5.1. Vascular protective effects of PPARs

All three PPAR isoforms are highly expressed in endothelial cells and to varying degrees in vascular smooth muscle, with PPAR β having the most widespread distribution [127] and probably the highest expression in pulmonary vessels [131,132]. Given that ligands of all three isoforms can promote vasorelaxation [133,134], including in the lung [131,135,136], strongly suggests that PPARs are likely to contribute to the blood pressure lowering effects of PGI $_2$ [61]. Perhaps in the case of PGI $_2$ itself, the mechanism occurs independent of the IP receptor, given IP $^{-/-}$ null mice are normotensive [53,64]. On the other hand, PPAR activation is likely to involve an increase in endothelial production of NO through phosphatidylinositolide 3-kinase-dependent eNOS phosphorylation and a reduction in ET-1 levels [133,134,137,138]. So far, the only PPAR isoform reported to significantly contribute to the vasorelaxing effect of PGI $_2$ analogues is PPAR β in pulmonary arterial smooth muscle [131,139]. In the former study, evidence was provided that PPAR β / δ mediated effects involved activation of the large conductance calcium-activated potassium channel in an IP receptor- and PKA-dependent but nitric oxide-independent manner in human PASMCS. In rat pulmonary artery, the IP receptor probably mediates treprostinil and beraprost induced activation of PPAR β [30,139].

Several studies have also shown increased VEGF production following treatment with PGI $_2$, iloprost, beraprost and treprostinil in many cell types both *in vivo* and *in vitro* [15,140,141]. This appears to be linked to cAMP and activation of the cAMP-responsive element binding protein (CREB) [142,143] but also reported to involve PPAR α [141] and PPAR β [144,145]. VEGF is linked to increased production of NO and PGI $_2$ in endothelial cells [146] and the stimulation of EPC proliferation to promote neovascularisation [147] or the formation of new blood vessels [141,144]. Thus PGI $_2$ activation of PPAR α and PPAR β may have a key role in maintaining endothelial cell integrity and regeneration. Indeed, both iloprost and treprostinil can increase the number and angiogenic potential of EPCs either in patients with PAH [148] or critical limb ischemia [149] and in an *in vitro* assay of endothelial tube formation [123]. In the latter, COX-1, PGI $_2$ S and PPAR β expression was strong in these human EPCs, and all critical for *in vivo* capillary formation when these specialised cells were transferred to nude mice [123]. Furthermore, the importance of VEGF in the context of maintaining vascular homeostasis in the lung is highlighted by studies showing that VEGF receptor blockade causes mild pulmonary hypertension (PH) and muscularisation of pulmonary arteries associated with endothelial cell death; when combined with chronic hypoxia, animals present with severe PAH and occlusive vascular lesions [13]. It is likely these regenerative mechanisms underpin the clinical benefit of these PGI $_2$ analogues in peripheral vascular disease as well as in Raynaud's phenomenon and digital ulcers associated with scleroderma [150,151]. Although cicaprost advanced into clinical trials, treatment of vasospasm in scleroderma patients was shown to be efficacious with iloprost but not with low-dose oral cicaprost [152], despite the latter having potent anti-platelet and blood-pressure effects in human volunteers [153]. Thus with the benefit of hindsight, perhaps lack of efficacy relates not only to the inability of cicaprost to bind and activate PPAR α / β but also its inability to

enhance VEGF expression and drive angiogenesis *in vivo* [121]. This is in direct contrast to iloprost.

PPAR γ in conjunction with the other PPARs is also likely to impact on endothelial cell function. Agonists of PPAR γ cause endothelial tube formation in an endothelial/interstitial cell co-culture assay as well as neovascularization *in vivo*, via an effect associated with increased production of VEGF [154]. Its knockdown in endothelial cells leads to an abnormal, proliferating, apoptosis-resistant phenotype [155], and mice develop spontaneous PAH [156]. PPAR γ expression in this cell type is reported to be down-regulated in PAH patients [9,155], suggesting that its loss may strongly impair endothelial cell function. The BMP receptor type 2 (BMPR2), loss of function mutations of which underlie the majority of heritable PAH, is known to be critical for maintaining endothelial cell homeostasis [7]. In work carried by Rabinovitch and colleagues, a BMPR2-mediated complex between PPAR γ and β -catenin was found to be critical for promoting pulmonary artery endothelial cell survival, proliferation, and migration via its transcriptional up-regulation of the apelin gene (reviewed in [6]). This and other work performed in the same laboratory, has provided compelling evidence that PPAR γ is a critical downstream target for BMPR2 in both endothelial and smooth muscle cells (Fig. 2).

PPARs can also play a role in the maintenance of a smooth muscle contractile cell phenotype. Thus, shear stress applied to endothelial cells co-cultured with smooth muscle cells resulted in increased smooth muscle cell PPAR α , β , γ ligand activity and increased contractile markers together with decreases in proinflammatory gene expression (MCP-1 and interleukin-8). However, knockdown of either endothelial PGI $_2$ S or PPARs confirmed a role for PPAR α and β but not PPAR γ [157]. In other studies, PPAR γ , appears to reduce neointimal hyperplasia by maintaining a smooth muscle contractile phenotype via either up-regulation of protein kinase G [158] and/or adiponectin [159].

To summarise, the data discussed above supports the increasing body of evidence that PGI $_2$ signalling through PPARs is part of a previously unrecognized mechanism that contributes to the vasoprotective and regenerative effects of PGI $_2$ on the endothelium, a subject which has also been extensively reviewed, mainly in the context of atherosclerosis [116,127] but also to maintaining a smooth muscle contractile phenotype.

5.2. IP receptor and PPARs as regulators of cell proliferation

Previous studies in normal human PASMCS have shown that PGI $_2$ analogues can inhibit the mitogenic responses to PDGF and serum in a largely cAMP-dependent manner, with adenylyl cyclase inhibitors blocking around 75% of the analogue responses in these cells [31,160]. Likewise, the growth rate of HEK-293 cells stably expressing the human IP receptor (HEK-IP) was substantially slower compared to cells expressing only the empty vector, and treprostinil inhibited cell growth in HEK-IP cells in a largely, but not exclusively cAMP-dependent manner, but one that also involved PPAR γ [9,125]. Cyclic AMP-dependent activation of PKA has been described to underlie PGI $_2$ analogue-dependent effects on cell proliferation induced by either serum [39], PDGR [39,161] or TGR- β 1 [11], though in most studies H-89 has been used which is known to block many kinases beside PKA [125].

The downstream mechanisms of how cAMP might inhibit growth are not well understood, but PGI $_2$ analogues appear to inhibit smooth muscle cell proliferation by blocking progression from G1 to S phase [161–163]. This may occur through phosphorylation of the cAMP response element binding protein (CREB) [39,162,164,165] with downstream targets including the inducible cAMP early repressor gene [161], cyclin A [162] and/or p21/p27 [164].




Fig. 2. Prostaglandins and peroxisome proliferator-activated receptor gamma (PPAR γ) ligands can enhance bone morphogenetic protein type II (BMPRII) signalling in PAH and oppose cell growth through platelet-derived growth factor (PDGF) and transforming growth factor β (TGF-1 β) receptor pathways. Upon ligand binding, the BMPRII receptor phosphorylates a type I receptor (ALK1, ALK2, ALK3 or ALK6) leading to the phosphorylation of Smad1/5/8. Upon phosphorylation of Smad4, this causes translocation of the phosphorylated Smads to the nucleus to modulate the expression of target genes (e.g. ApoE and adiponectin) that inhibit growth, promote apoptosis and maintain a smooth muscle cell (SMC) phenotype. Upon TGF β ligand binding, the TGF-1 β type II receptor phosphorylates a type I receptor, ALK5. This leads to phosphorylation of Smad2/3 which phosphorylates Smad4, with the complex translocating to the nucleus. Activation of this receptor will also lead to activation of extracellular signal regulated kinases (ERKs), which can be inhibited by PPAR γ and prostacyclin analogues. ERK activation limits the phosphorylation of Smad1/5. Stimulation of ERK by the PDGF and TGF β receptor tyrosine kinases can also further limit Smad c-terminus phosphorylation. These effects are integrated at the level of inhibitory DNA binding protein 1 (Id1) gene expression, which can also be activated by prostacyclin analogues independently of SMADs.

There are other mechanisms by which cAMP cascades can impede cell growth (Fig. 2). PGI $_2$ analogues can suppress TGF- β signalling either through inhibiting phosphorylation of SMAD 2/3 [11,165] or through SMAD independent dephosphorylation of p38 MAPK [11]. Analogues can also up-regulate BMPRII signalling through enhanced BMP phosphorylation of SMAD 1/5 and expression of inhibitory DNA binding protein 1 (Id1), the latter occurring irrespective of BMP ligand activation and SMAD phosphorylation [39]. In other studies, treprostinil inhibits serum-induced cell growth in human PSMCs in part through cAMP-dependent activation of ATP-sensitive potassium K $^+$ channels [166]. Recently mutations in TASK-1, a background potassium current switched off by hypoxia and ET-1 in human PSMCs, gives rise to a rare form of heritable PAH [167]. Moreover, PGI $_2$ analogues can activate this current, and possibly rescue trafficking defects in TASK-1, but the role of this current in driving pulmonary cell proliferation and remodelling remains to be determined. In aortic smooth muscle cells, cAMP elevating agents inhibit PDGF-induced proliferation through inhibition of the calcineurin and NFAT (nuclear factor of activated T-cells) pathway [168]. The exact mechanism was not fully explored, but PKA is known to promote the nuclear export of the calcineurin/NFAT complex, while a lowering of intracellular calcium levels would inhibit the phosphatase activity of calcineurin directly, thereby maintaining NFAT in the phosphorylated state and preventing its translocation into the nucleus (see Refs. [4,168]). Such a mechanism may counteract the elevated calcineurin/NFAT activity and expression reported either in IPAH or in

remodeled pulmonary arteries [169]. Furthermore, this transcription factor appears largely responsible for the down-regulation of voltage-gated (Kv) current and Kv1.5 expression reported in human PSMCs from these patients as well as the expression of pro-inflammatory cytokines and growth-promoting genes (including ET-1) in a number of different cell types [4,170]. PGI $_2$ analogues have been reported to reduce ET-1 synthesis stimulated by mitogens in PSMCs [45,171] and to reduced elevated plasma levels in patients with systemic sclerosis [172]. Whether this relates to inhibition of NFAT activity, which itself can be suppressed by a direct interaction of PPAR γ [16], remains to be determined, but likely to play a significant role. Moreover, PPAR γ negatively regulates store-operated Ca $^{2+}$ entry (SOCE) through the down regulation of TRPC1 and TRPC6 [128], which may impact indirectly on calcineurin/NFAT signalling.

Activation of PPARs is also likely to contribute to the antiproliferative effects of prostacyclin drugs in a variety of cell types. Recent studies have shown that PPAR γ contributes in part to antiproliferative effects to PGI $_2$ analogues in normal PSMCs [9] and interestingly also to the PDE5 inhibitor, sildenafil [128]. In other studies, iloprost-induced inhibition of tumorigenesis in the lung was shown to be mediated by PPAR γ . Thus, pulmonary-specific overexpression of either PGI $_2$ S or PPAR γ resulted in suppression of tumour incidence and multiplicity in these lung models, while gene deletion of the IP receptor had no effect on tumour growth [122]. Furthermore, non-small cell lung cancer cells over-expressing PPAR γ exhibit significantly less invasiveness and

metastases [122]. Taken together, this suggests a key role for both PGI₂ and PPAR γ in regulating cancer progression. A contribution from PPAR β was ruled out on the basis that iloprost could not activate a PPAR β -specific response element in lung epithelial cells [122]. This contrasts with other studies where PPAR β appears to mediate the antiproliferative effects of treprostinil in human lung fibroblasts [173] or beraprost in cultured aortic smooth muscle [120,164]. A consistent finding with many of the studies described above is that direct PPAR activation by analogues occurs at higher concentrations than those required to activate IP receptors. This would fit in with the observation that iloprost binding to the crystallised ligand-binding domain of PPAR α or β occurs with an EC₅₀ of ~200 nM [119]. Accepting the limitations of the somewhat artificial nature of this study, suggests some PPAR effects could lie outside the therapeutic concentration range or require up-titration of the prostacyclin drug beyond the initial hemodynamic response.

The role of PPAR β in the cardiovascular system is complex, since over expression of PPAR β actually promotes vascular smooth muscle proliferation and atherosclerosis [127] and has tumorigenic effects [116]. Furthermore, PPAR β activation is consistently associated with human lung carcinoma cell growth (e.g. [174]). In contrast, PPAR β ligands appear to do the opposite and inhibit PDGF-mediated effects on human PASMCs proliferation, and migration [132]. A degree of caution must however be exercised when interpreting data using PPAR β ligand activators in isolation, as the vasorelaxing effect of GW0742 in pulmonary and mesenteric artery was not altered in PPAR β null mice [175], suggesting PPAR β independent effects of some ligand activators.

6. Impact of pulmonary hypertension on PGI₂ signalling

Several studies point to multiple defects in PGI₂ signaling pathway in PAH which may either contribute to disease pathology and/or explain why PGI₂ therapy wanes as the disease progresses, necessitating doses to be escalated. Decreased urinary levels of the PGI₂ metabolite, 2,3-dinor-6-keto-PGF_{1 α} are found in patients with IPAH [176] and pulmonary hypertension (PH) linked with congenital heart disease [177,178]. In IPAH this is associated with a progressive loss of PGI₂S expression from large to small pulmonary arterial vessels, with virtually no expression in plexiform lesions [179]. In other forms of PH, PGI₂S protein is reduced in a fetal lamb model of persistent PH of the newborn, where synthase activity was also found to be decreased by protein tyrosine nitration [180]. In the context of PAH, PGI₂S is protective as over-expression in monocrotaline- and hypoxia- induced models of PAH in rodents, reduced both medial thickening and pulmonary pressure [181,182], while in a bleomycin model of acute lung injury, pulmonary fibrosis, lung inflammation and mortality were attenuated [183]. Moreover, individuals from families with heritable PAH, that had a bias for PGI₂S promoter polymorphisms with increased transcriptional activity, had a lower risk of developing PAH [184], demonstrating a protective effect of the synthase in humans. With respect to the IP receptor, a reduction in message and protein levels have been reported in IPAH lungs or in rats following monocrotaline treatment [9,93], although in the former study, down regulation in the smooth muscle cells was reported to be driven by drug treatment rather than the disease itself, but not in intimal proliferating cells, where expression was weak regardless. IP receptor loss is however unlikely to cause PAH as mice lacking the IP receptor gene do not spontaneously develop PH, although they are more susceptible to the hypertensive and remodeling effects of hypoxia [64]. Polymorphisms in the IP receptor have been associated with platelet disorders and with accelerated atherosclerotic disease in humans [185], but so far have not been directly linked to PAH. Thus there is good

evidence that the dysfunction of both PGI₂S and the IP receptor is likely to contribute to the pathology and disease severity in PAH.

IP receptor signalling may also be hampered by increases in the expression and activity of PDEs. Phosphodiesterases comprise a family of at least 11 isoforms (PDE1–PDE11) that each has a different capacity for hydrolyzing cAMP, cGMP, or both nucleotides [186]. Elevated message and protein levels of PDE1 (PDE1A and PDE1C), PDE5 and to a lesser extent PDE3 (PDE3A and PDE3B), along with heightened activity of these PDEs have been reported in IPAH [50,51,91]. Taken together, this suggests that reduced effectiveness of PGI₂ and its analogues due to enhanced cAMP breakdown is likely to occur in PAH. Indeed, blockade of PDE1 and PDE3 restored the ability of beraprost to increase cAMP levels in PASMCs derived from IPAH patients [51]. Furthermore, targeted knockdown of PDE1C with siRNA enhanced cAMP accumulation and inhibited cell growth more in human PASMCs from PAH patients than from controls [51]. In other studies, aortic smooth muscle cells from PDE3A^{-/-} mice were less responsive to PDGF compared to cells from wild type or PDE3B^{-/-} mice, in part due to PKA-mediated CREB phosphorylation, higher levels of p53 and reduced ERK-1/2 phosphorylation [187]. Thus, a key role of PDE1 and PDE3 in modulating cAMP levels and growth responses to PGI₂ analogues would fit with the observation that only a combination of a PDE1 or PDE3 inhibitor with iloprost could reverse PH and distal pulmonary artery muscularization induced by chronic hypoxia [50]. Likewise, in a chronic monocrotaline model, combined administration of iloprost and a mixed PDE3/4 PDE inhibitor was required to fully normalize hemodynamic and right heart changes when administered after full establishment of PH [38]. Taken together, these findings indicate that upregulation of PDE1C and PDE3 play a role in the structural remodeling process underpinning PAH and suggests that a PDE1 inhibitor and/or a PDE3 inhibitor might be useful in potentiating analogue effects in the clinical setting. This is probably happening to an extent when prostacyclins are combined with the PDE5 inhibitors, as PDE3-mediated hydrolysis of cAMP should theoretically be inhibited by cGMP and thus augment cAMP levels in response to prostacyclins, as recently described for treprostinil and tadalafil [188]. Sildenafil in particular is likely to inhibit PDE1 activity at therapeutic doses [186] either directly (K_i for inhibition ~280 nM) or indirectly through reducing intracellular calcium and thereby the calmodulin interaction with PDE1 [51]. The latter is almost certainly likely to happen when combining with prostacyclins. Taken together, this provides a scientific rationale for the increasing number of reports showing improved hemodynamics, lengthened time to clinical worsening, and increased survival when PDE5 inhibitors are combined with prostacyclins (see Refs. [186,188]). Very recently, milrinone (PDE3 and PDE4 inhibitor) combined with inhaled PGI₂ has been assessed retrospectively in 60 high risk patients having PH after coronary bypass surgery and was shown to reduce PAP without a fall in systemic blood pressure, increase cardiac index and reduce vasoconstrictor support [189]. While there are clearly limitations with the study, such an approach warrants further investigation clinically. Cilostazol, a more selective PDE3 inhibitor, which is currently in clinical use for intermittent claudication [190], might also be considered in combination with prostacyclins.

Recently other dual substrate PDEs isoforms, which may be targeted clinically or be involved in disease progression in PAH, have recently been documented [191,192]. Strong immunoreactivity for PDE10A, compared to weak expression in control lungs, was observed predominantly in the medial layer of pulmonary arteries in both the lungs of IPAH patients and in rats following monocrotaline, while siRNA knockdown in PASMCs reduced proliferation by around 40% [191]. In very recent studies, a highly selective and potent PDE2 inhibitor, BAY 60-7550 elicited pulmonary dilation, prevented pulmonary vascular remodeling, and

reduced right ventricular hypertrophy [192]. In addition this PDE2 inhibitor potentiated the effects of treprostinil, an NO donor, sildenafil or atrial natriuretic peptide (with a neutral endopeptidase inhibitor) in established PAH. Thus this dual selective PDE inhibitor may collectively enhance NO and cAMP signalling and may be a novel approach in PAH.

For a number of reasons, IP receptor desensitization is likely to be a problem with the long-term use of PGI₂. Analogues are known to induce rapid time- and concentration-dependent phosphorylation and internalization of the IP receptor [193], with desensitisation lasting for several hours after agonist removal [194]. The mechanism of receptor desensitization is multifactorial and involves both PKA and protein kinase C (PKC). Cross-desensitization can also occur via EP₁ [52] or TP receptors [195], being activated either by PGI₂ mimetics themselves or by increased production of their respective endogenous ligands, PGE₂ or thromboxane A₂, both of which are elevated in lung disease [176,196]. Thus in conjunction with high PDE activity, receptor desensitization, may contribute to the lack of responsiveness of PGI₂ agents in advanced disease. Interestingly, EP₂ receptors, which are a major target for treprostinil, do not readily undergo receptor desensitisation in human airway smooth muscle or in COS cells over expressing these receptors under conditions where other Gs coupled receptors do [197].

The extent to which IPAH impacts on PPAR isoform expression is relatively unexplored. Over 10 years ago, Ameshima and colleagues reported reduced staining of PPAR γ in IPAH lungs [155], as was recently reported in lung tissue samples and in airway epithelial cells of patients with severe chronic obstructive pulmonary disease [198]. Likewise, PPAR γ expression was significantly reduced in the lungs of rodents with hypoxia-induced PH [128,135,199] and also in the vascular lesions in a rat model of severe PAH caused by hypoxia in the presence of a VEGF blocker [155]. In endothelial cells and in the proliferating cells within the intima and plexiform lesions, PPAR γ expression was non-existent [155], a finding subsequently confirmed in our laboratory [9]. Moreover PPAR γ knockdown in endothelial cells leads to an abnormal, proliferating, apoptosis-resistant phenotype [155] and in vivo mice develop PAH and muscularization of distal pulmonary arteries occurs [156]. Given that PPAR γ , along with the IP receptor and PGI₂S, are all minimally expressed in intimal proliferating cells, suggests that loss/lack of all three targets may be significantly contributing to hyperproliferation as well as influencing disease severity. However, while targeted deletion of PPAR γ in smooth muscle is also known to cause PAH [200], we actually found its expression to be markedly up-regulated in the medial layer of distal pulmonary arteries taken from the lungs of children with endstage PAH disease, and in contrast to the IP receptor, expression was unaffected by drug treatment [9]. Furthermore, we showed that human PSMCs from PAH patients were sensitive to the growth suppressing effects of the PPAR γ activator, rosiglitazone, which potentiated the antiproliferative effects of treprostinil [9]. Thus PPAR γ upregulation in smooth muscle may actually serve as a compensatory mechanism to limit vascular remodeling in PAH. Consistent with this notion, PPAR γ expression was reported to be increased in the smooth muscle layers from asthmatic patients [201] as well as in atherosclerotic lesions [127]. The factors regulating PPAR γ expression in PAH are not well defined, although the pro-inflammatory cytokine, IL-4 appears to be intrinsically linked to the induction of a cluster of genes associated with the PPAR γ pathway [202]. This includes the gene itself and three enzymes ALOX15 (arachidonate 15-lipoxygenase), MAOA (monoamine oxidase) and ENPP2 (ectonucleotide pyrophosphatase/phosphodiesterase family member 2), whose activity can potentially generate endogenous PPAR γ ligands, namely activators like, 13-hydroxyoctadecadienoic acid (13-HODE), 5-hydroxyeicosatetraenoic acid (15-HETE) and

lysophosphatidic acid [202]. In PAH, it is possible that patients treated with sildenafil, may have enhanced PPAR γ expression, as cGMP/PKG is linked to its upregulation in chronic hypoxia in rats [128].

Currently there is no information about what happens to PPAR α and β in PAH, although PDGF was found to increase PPAR β expression and protein levels by 4-fold in human PSMCs [132], suggesting its expression may be unregulated in PAH, at least in smooth muscle. PPAR α will suppress hypoxia-inducible factor α and ET-1 levels [203], so its loss may exacerbate the effects of hypoxia.

7. Role of PPARs in lung remodelling in the context of PAH

Several lines of evidence suggest PPARs are also targets in lung disease where proliferation, remodelling and inflammation are key components [16,130,137,204]. Iloprost or pulmonary-specific over expression of either PGI₂S or PPAR γ was reported to result in suppression of tumour incidence and multiplicity in lung models [122]. In contrast, gene deletion of the IP receptor had no effect on tumour growth nor was the response to iloprost inhibited in these mice [122]. Furthermore, non-small cell lung cancer cells over-expressing PPAR γ exhibited significantly less tumor invasiveness and metastases. As already mentioned, the role of PPAR γ in vascular remodelling in the lung is strongly implicated as targeted deletion of PPAR γ in either smooth muscle or endothelial cells causes PAH and muscularization of distal pulmonary arteries [156,200]. In contrast, PPAR γ ligands (e.g. rosiglitazone or nitro-fatty acids) enhance the antiproliferative effects of treprostinil in human PSMCs from PAH patients [9] and protect against the pulmonary effects of monocrotaline and hypoxia in a number of PAH animal models [6,135,137]. In addition, PPAR γ ligands can protect against neointimal hyperplasia induced by vascular injury [158] or a proinflammatory phenotype induced in epithelial cells by cigarette smoke [198]. Key mechanisms by which PPAR γ attenuates remodelling in PAH appear to involve a dampening of PDGF receptor β (PDGFR β) signalling through receptor internalisation and reduced ERK1/2 phosphorylation and a rescue of BMP receptor type II (BMPRII) dysfunction ([6] and Fig. 2). Likewise, beraprost was not only able to inhibit the proliferation of PSMCs expressing a mutant BMPRII receptor identified in PAH patients more effectively than wild-type cells, but it could also reverse aberrant proliferation to TGF β [11]. A similar finding was reported for other analogues [205]. Taken together, this suggests that prostacyclins may be beneficial in the treatment of heritable PAH where BMPRII mutations have been identified. Indeed, only intravenous prostacyclin strongly improved functional class in this group of patients, whereas other therapies were largely ineffectual [206].

As already mentioned, the role of PPAR β in vascular remodelling in the cardiovascular system is not well understood and complex since over expression of PPAR β can drive vascular smooth muscle proliferation and angiogenesis in cancer, while PPAR β ligands appear to do the opposite [116,127]. In other studies, PPAR β ligands reduce cardiac hypertrophy and fibrosis in a pulmonary artery banding model while having no effect on vascular remodelling in a hypoxia-driven PAH model [207].

Activation of extracellular matrix proteins MMPs are known to contribute to structural remodeling by growth factor activation and degradation of the internal elastic lamina. Furthermore, in monocrotaline-treat animals, increases in MMP-9 and MMP-2 protein levels and activity were somewhat suppressed by iloprost treatment, but co-treatment was required with a PDE3/4 inhibitor to have significant effects and return levels to those seen in control animals [38]. The mechanism of suppression is likely to involve




Fig. 3. Anti-inflammatory actions of PGI₂ and PPARs. Endothelial dysfunction, associated with the expression of adhesion molecules, adherence of leukocytes to the injured endothelium, and an environment where pro-inflammatory cytokines are produced by endothelial and various inflammatory cell types (not shown), is common place in pulmonary arterial hypertension. TNF α , through activation of the transcription factor, NF- κ B is a potent driver of these events and has often been used experimentally to investigate analogue and PPAR driven effects on inflammatory mediators. Prostacyclin and its analogues are potent inhibitors of inflammation, where NF- κ B is suppressed through IP receptor activation and may involve Epac-dependent activation of Rac-1 or PPAR activation either through the receptor or via direct binding. The role of PPARs in mediating the effects of PGI₂ is assumed rather than being directly investigated. AC, adenylyl cyclase; cAMP, cyclic adenosine monophosphate; Gs, stimulatory G protein; PKA, protein kinase A; COX, cyclooxygenase; EPAC, exchange protein activated by cAMP; ICAM, intercellular adhesion molecule; IF γ , interferon- γ ; IL-1, interleukin-1; IL-6, interleukin-6; IP, prostacyclin receptor; NF- κ B, nuclear factor kappa B; PGI₂, prostacyclin; PGH₂, prostaglandin H₂; PKA, protein kinase A; PPAR, peroxisome proliferator-activated receptor α , γ ; Rac-1, Ras-related C3 botulinum toxin substrate 1; TNF- α , tumour necrosis factor; VCAM, vascular cell adhesion molecule-1.

cAMP, though PPAR α and PPAR γ ligands are also potent suppressors of MMP-9 and MMP-2 activity [16].

The effects of prostacyclins on remodelling markers in patients is largely unknown though clinical improvement with treprostinil treatment for 12 weeks in a placebo controlled trial was correlated with a reduction in angiotensin-2 and MMP-9 plasma levels with a trend towards lower PDGF levels [15]. Interestingly, in an experimental model of flow-mediated PH, improvement in right ventricular function with iloprost was associated with a restoration of capillary to myocyte ratio, with no detectable change in vascular remodeling or pulmonary arterial pressure, suggesting new capillary growth may improve a failing heart [208]. It should be noted that this study failed to detect any changes in message levels for VEGF or angiotensin-2 after iloprost treatment for 28 days. Given that markers were measured at the same time point as histological changes were recorded, may indicate that this was too late to pick up changes associated with new vessel growth.

8. Anti-inflammatory actions of prostacyclins

Endothelial dysfunction plays a key role in the development of PAH and this in turn causes the expression of adhesion molecules (e.g. P-selectin, ICAM-1) and the subsequent adherence of platelets and leukocytes to the injured endothelium [14,209,210]. Extensive infiltration of T-lymphocytes, macrophages and dendritic cells occurs in the distal arteries and plexiform lesions of children and adults with IPAH [13,14,209] culminating in an environment where pro-inflammatory cytokines, particularly interleukins 1 (IL-1) and 6 (IL-6) and chemokines (e.g. CCL2, also known as monocyte chemoattractant protein, MCP-1) are up-regulated [7,14]. It is becoming increasingly recognised that the anti-inflammatory actions of PGI₂ may contribute to the beneficial effects of these agents in PAH as well as in critical limb ischaemia, scleroderma and diabetes. PGI₂, iloprost and beraprost are capable of inhibiting the expression of selectins (P and E) and the adhesion molecules ICAM and vascular cell adhesion molecule-1 (VCAM) in endothelial (Fig. 3) or inflammatory cells of patients with PAH, systemic sclerosis, peripheral vascular disease and type 2 diabetes mellitus [36,172,211,212].

These effects will all serve to reduce leukocyte–endothelium interactions during inflammation [213]. In diabetic patients treated with beraprost for three years, low VCAM levels were associated with a significantly reduced intimal-media thickness of carotid arteries compared to untreated diabetics [212]. The mechanism associated with adhesion molecule suppression is not well understood, but a number of studies show analogue effects can be mimicked by cAMP and are sensitive to adenylyl cyclase or Rac1 inhibitors [213–215]. Apart from one study [214], the role of the IP receptor has not specifically been investigated, though given that cicaprost could significantly inhibit TNF- α – and IL-1 β -induced cell expression of ICAM-1 and VCAM-1 in cultured human coronary smooth muscle [216] suggests a likely role for this receptor.

Furthermore, analogues can down regulate pro-inflammatory cytokine (TNF- α , IL-1 IL-6 and interferon- γ) and chemokine production (e.g. monocyte chemoattractant protein 1, MCP-1; granulocyte macrophage colony-stimulating factor, GM-CSF; macrophage inflammatory protein 1, MIP-1) in response to bacterial products (endotoxin) in alveolar macrophages [217], monocytes [218,219], dendritic cells [220] and T-lymphocytes [221]. More often than not, suppression of proinflammatory cytokines and chemokines in these studies, occurred in a largely, though not exclusively IP receptor driven manner [218,220,221] and in part involving PPAR γ [219], though other studies failed to confirm a role for PPARs [218]. NF- κ B plays a critical role in the downstream effects of endotoxin, with analogues shown to suppress NF- κ B activity in these inflammatory cell types [217,220,221], though one study reported that the mitogen-activator protein kinase pathway (MAPK) may instead be the target [219].

Studies in patients are limited, though iloprost inhibited plasma TNF α levels in critical limb ischemia [222]. In IPAH, eprostamol treatment reduced elevated circulating levels of MCP-1 [223] and in combination with bostantan, significantly reduced human leukocyte antigen-DR expression, a marker of endothelial cell activation [209]. Whether PPARs play a significant role in analogue suppression of inflammatory mediators remains largely undetermined, though in the lung, PPAR α and, to a lesser extent, PPAR γ are key regulators of adhesion molecule expression while both PPARs

are major inhibitors of pro-inflammatory cytokine production via transrepression of NF- κ B [127,198,204]. By comparison, little is known about the role of PPAR β , but it has been implicated in the antithrombotic effects of treprostinil in human platelets [103].

9. Concluding remarks

PGI₂ can no longer be considered a hormone that just produces its biological effects through activation of the IP receptor. The family of transcription factors known as PPARs must now be considered a target through which PGI₂ or its stable analogues can modulate cell growth, endothelial cell activation, inflammation and apoptosis and produce beneficial effects in PAH. While PPARs can be activated independently of the IP receptor, few studies have considered the role membrane receptors (or for that matter cAMP) either in inducing activation or modulating ligand binding. The future challenge will be in identifying the role of specific PPAR isoforms not only in the aetiology of PAH, but also in response to analogue activation. The role of VEGF in PAH (vascular protective verses angiogenic) is clearly an area that needs further investigation, in particular whether up-regulation of this growth factor by PGI₂ analogues is detrimental in PAH patients and/or contributes to lack of efficacy in end-stage disease. Given that the aim of any treatment is to reverse the remodelling process, then the possibility of earlier and aggressive intervention with PGI₂ agonists should be considered. Finally, PGI₂ agonists differ considerably in their pharmacological profile, meaning the clinician should not assume they are dealing with a homogenous class of agents. It may be that such differences can be exploited in future therapies or be utilised to tease out the role of different prostanoid receptor subtypes in PAH. Thus, PGI₂ agonists can act upon different membrane and nuclear receptor targets meaning a similar spectrum of therapeutic benefit or side effect profile cannot be readily assumed with this class of agents. Both EP₂ and DP₁ receptors must now be considered viable clinical targets for treprostinil in PAH, and so their role in this disease requires further investigation, particularly in relation to the new generation of non prostanoid IP agonists, which have been specifically developed for high selectivity towards the IP receptor.

Disclosures

The research work was funded by the Medical Research Council and British Heart Foundation. Prof. Clapp has also received honoraria and research educational grants from United Therapeutics, Pfizer, and Lung Biotechnology and has served as a consultant for Arena, Bayer, Concept Pharmaceuticals, Cytokinetics, and United Therapeutics.

References

- McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. *J Am Coll Cardiol* 2009;53:1573–619.
- D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. *Ann Intern Med* 1991;115:343–9.
- Sandoval J, Bauerle O, Gomez A, Palomar A, Martinez Guerra ML, Furuya ME. Primary pulmonary hypertension in children: clinical characterization and survival. *J Am Coll Cardiol* 1995;25:466–74.
- Malenfant S, Neyron AS, Paulin R, et al. Signal transduction in the development of pulmonary arterial hypertension. *Pulm Circ* 2013;3:278–93.
- Davie NJ, Schermuly RT, Weissmann N, Grimminger F, Ghofrani HA. The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies. *Eur J Clin Invest* 2009;39(Suppl. 2):38–49.
- Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. *J Clin Invest* 2012;122:4306–13.
- Tuder RM, Archer SL, Dorfmueller P, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. *J Am Coll Cardiol* 2013;62:D4–12.
- Zhang S, Patel HH, Murray F, et al. Pulmonary artery smooth muscle cells from normal subjects and IPAH patients show divergent cAMP-mediated effects on TRPC expression and capacitative Ca²⁺ entry. *Am J Physiol Lung Cell Mol Physiol* 2007;292:L1202–10.
- Falcetti E, Hall SM, Phillips PG, et al. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2010;182:1161–70.
- Morrell NW, Yang X, Upton PD, et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor- β 1 and bone morphogenetic proteins. *Circulation* 2001;104:790–5.
- Ogo T, Chowdhury HM, Yang J, et al. Inhibition of overactive transforming growth factor- β signaling by prostacyclin analogs in pulmonary arterial hypertension. *Am J Respir Cell Mol Biol* 2013;48:733–41.
- Frid MG, Li M, Gnanasekharan M, et al. Sustained hypoxia leads to the emergence of cells with enhanced growth, migratory, and prometogenic potentials within the distal pulmonary artery wall. *Am J Physiol Lung Cell Mol Physiol* 2009;297:L1059–72.
- Stenmark KR, Meyrick B, Galie N, Mooi WJ, Mcmurtry IF. Animal models of pulmonary arterial hypertension: The hope for etiologic discovery and pharmacologic cure. *Am J Physiol Lung Cell Mol Physiol* 2009;297:L1013–32.
- Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. *J Am Coll Cardiol* 2009;54:S10–9.
- Hiremath J, Thanikachalam S, Parikh K, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. *J Heart Lung Transplant* 2010;29:137–49.
- Becker J, ayre-Orthez C, Frossard N, Pons F. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? *Fundam Clin Pharmacol* 2006;20:429–47.
- Chazova I, Loyd JE, Zhdanov VS, Newman JH, Belenkov Y, Meyrick B. Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. *Am J Pathol* 1995;146:389–97.
- Stenmark KR, Rabinovitch M. Emerging therapies for the treatment of pulmonary hypertension. *Pediatr Crit Care Med* 2010;11:S85–90.
- Pullamsetti SS, Schermuly R, Ghofrani A, Weissmann N, Grimminger F, Seeger W. Novel and emerging therapies for pulmonary hypertension. *Am J Respir Crit Care Med* 2014;189:394–400.
- McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. *Circulation* 2002;106:1477–82.
- Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. *Chest* 2006;129:1636–43.
- Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. *Eur Respir J* 2006;28:1195–203.
- Skoro-Sajer N, Lang I, Naeije R. Treprostinil for pulmonary hypertension. *Vasc Health Risk Manage* 2008;4:507–13.
- Sadushi-Kolici R, Skoro-Sajer N, Zimmer D, et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. *J Heart Lung Transplant* 2012;31:735–43.
- Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. *Eur Heart J* 2005;26:1895–902.
- Knudsen L, Schurawlew A, Nickel N, et al. Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy. *BMC Pulm Med* 2011;11:56.
- Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. *J Am Coll Cardiol* 2003;41:2119–25.
- Clapp LH, Patel JA. The mechanistic basis for prostacyclin action in pulmonary hypertension. *Int J Respir Care* 2010;27–33.
- Whittle BJ, Silverstein AM, Mottola DM, Clapp LH. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP₁ and EP₂ agonist. *Biochem Pharmacol* 2012;84:68–75.
- Orie NN, Ledwozyw A, Williams DJ, Whittle BJ, Clapp LH. Differential actions of the prostacyclin analogues treprostinil and iloprost and the selezipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins. *Prostaglandins Other Lipid Mediat* 2013;106:1–7.
- Clapp LH, Finney PA, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogues on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. *Am J Respir Cell Molec Biol* 2002;26:194–201.
- Reeves JT, Groves BM, Turkevich D. The case for treatment of selected patients with primary pulmonary hypertension. *Am Rev Respir Dis* 1986;134:342–6.
- Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. *Circulation* 2005;111:3105–11.
- Fishman AP. Pulmonary hypertension – beyond vasodilator therapy. *N Engl J Med* 1998;338:321–2.
- McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. *Chest* 2004;126:78S–92S.

- [36] Zardi EM, Zardi DM, Cacciapaglia F, et al. Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogs. *Int Immunopharmacol* 2005;5:437–59.
- [37] Kawabe J, Ushikubi F, Hasebe N. Prostacyclin in vascular diseases – recent insights and future perspectives. *Circ J* 2010;74:836–43.
- [38] Schermuly RT, Kreiselmeier KP, Ghofrani HA, et al. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolfenetrine in chronic experimental pulmonary hypertension. *Circ Res* 2004;94:1101–8.
- [39] Yang J, Li X, Al-Lamki RS, et al. Smad-dependent and Smad-independent induction of Id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo. *Circ Res* 2010;107:252–62.
- [40] Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. *J Clin Invest* 2008;118:2372–9.
- [41] Rhodes CJ, Davidson A, Gibbs JS, Wharton J, Wilkins MR. Therapeutic targets in pulmonary arterial hypertension. *Pharmacol Ther* 2009;121:69–88.
- [42] Patel JA, Hall SM, Abraham DJ, Nelsen AC, Silverstein AM, Clapp LH. Comparison of current therapies to inhibit endothelin-induced growth of pulmonary artery smooth muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension. *Eur Respir J* 2014;44(Suppl. 58):P2355.
- [43] Hall SM, Davie N, Klein N, Haworth SG. Endothelin receptor expression in IPAH: effect of bosentan and epoprostenol treatment. *Eur Respir J* 2011;38:851–60.
- [44] Schneider MP, Boesen EI, Pollock DM. Contrasting actions of endothelin ET_A and ET_B receptors in cardiovascular disease. *Annu Rev Pharmacol Toxicol* 2007;47:731–59.
- [45] Wort SJ, Woods M, Warner TD, Evans TW, Mitchell JA. Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling. *Am J Respir Cell Mol Biol* 2001;25:104–10.
- [46] Kelly LK, Wedgwood S, Steinhorn RH, Black SM. Nitric oxide decreases endothelin-1 secretion through the activation of soluble guanylate cyclase. *Am J Physiol Lung Cell Mol Physiol* 2004;286:L984–91.
- [47] Gryglewski RJ. Prostacyclin among prostanoids. *Pharmacol Rep* 2008;60:3–11.
- [48] Jakubowski JA, Utterback BG, Mais DE, et al. Biochemical and pharmacological activity of arene-fused prostacyclin analogues on human platelets. *Prostaglandins* 1994;47:189–201.
- [49] Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structure, properties, and functions. *Physiol Rev* 1999;79:1193–226.
- [50] Phillips PG, Long L, Wilkins MR, Morrell NW. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. *Am J Physiol Lung Cell Mol Physiol* 2005;288:L103–15.
- [51] Murray F, Patel HH, Suda RY, et al. Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1. *Am J Physiol Lung Cell Mol Physiol* 2007;292:L294–303.
- [52] Schermuly RT, Pullamsetti SS, Breitenbach SC, et al. Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. *Respir Res* 2007;8:4.
- [53] Murata T, Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. *Nature (London)* 1997;388:678–82.
- [54] Rubin LJ, Groves BM, Reeves JT, Frosolone M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. *Circulation* 1982;66:334–8.
- [55] Jones DK, Higenbottam TW, Wallwork J. Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin). *Br Heart J* 1987;57:270–8.
- [56] Gryglewski RJ. Effects of prostacyclin in atherosclerotic vascular disease. *Adv Prostaglandin Thromboxane Leukot Res* 1985;15:539–42.
- [57] Fredrich M, Muller B. Prostacyclin and atherosclerosis. In: Rubanyi GM, Vane JR, editors. *Prostacyclin: new perspectives for basic research and novel therapeutic indications*. Elsevier Science Publishers; 1992. p. 169–80.
- [58] Numaguchi Y, Naruse K, Harada M, et al. Prostacyclin synthase gene transfer accelerates reendothelialization and inhibits neointimal formation in rat carotid arteries after balloon injury. *Arterioscler Thromb Vasc Biol* 1999;19:727–33.
- [59] Todaka T, Yokoyama C, Yanamoto H, et al. Gene transfer of human prostacyclin synthase prevents neointimal formation after carotid balloon injury in rats. *Stroke* 1999;30:419–26.
- [60] Hara S, Morishita R, Tone Y, et al. Overexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells. *Biochem Biophys Res Commun* 1995;216:862–7.
- [61] Yokoyama C, Yabuki T, Shimonishi M, et al. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. *Circulation* 2002;106:2397–403.
- [62] Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. *Science* 2004;306:1954–7.
- [63] Kobayashi T, Tahara Y, Matsumoto M, et al. Roles of thromboxane A₂ and prostacyclin in the development of atherosclerosis in apoE-deficient mice. *J Clin Invest* 2004;114:784–94.
- [64] Hoshikawa Y, Voelkel NF, Gesell TL, et al. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. *Am J Respir Crit Care Med* 2001;164:314–8.
- [65] Hara A, Yuhki K, Fujino T, et al. Augmented cardiac hypertrophy in response to pressure overload in mice lacking the prostaglandin I₂ receptor. *Circulation* 2005;112:84–92.
- [66] Francois H, Athirakul K, Howell D, et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. *Cell Metab* 2005;2:201–7.
- [67] Kawabe J, Yuhki K, Okada M, et al. Prostaglandin I₂ promotes recruitment of endothelial progenitor cells and limits vascular remodeling. *Arterioscler Thromb Vasc Biol* 2010;30:464–70.
- [68] Aburakawa Y, Kawabe J, Okada M, et al. Prostacyclin stimulated integrin-dependent angiogenic effects of endothelial progenitor cells and mediated potent circulation recovery in ischemic hind limb model. *Circ J* 2013;77:1053–62.
- [69] Whittle BJ, Moncada S. Antithrombotic assessment and clinical potential of prostacyclin analogues. In: Ellis GP, West GB, editors. *Progress in medical chemistry*. North Holland: Elsevier Science Publishers; 1984. p. 237–79.
- [70] Demolis JL, Robert A, Mouren M, Funck-Brentano C, Jaillon P. Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers. *J Cardiovasc Pharmacol* 1993;22:711–6.
- [71] Olschewski H, Rose F, Schermuly R, et al. Prostacyclin and its analogues in the treatment of pulmonary hypertension. *Pharmacol Ther* 2004;102:139–53.
- [72] Wade M, Baker FJ, Roscigno R, et al. Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion. *J Clin Pharmacol* 2004;44:503–9.
- [73] Benyahia C, Boukais K, Gomez I, et al. A comparative study of PGI₂ mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor. *Prostaglandins Other Lipid Mediat* 2013;107:48–55.
- [74] Skoro-Sajer N, Lang IM. Selexipag for the treatment of pulmonary arterial hypertension. *Expert Opin Pharmacother* 2014;15:429–36.
- [75] Kuwano K, Hashino A, Asaki T, et al. 2-[4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. *J Pharmacol Exp Ther* 2007;322:1181–8.
- [76] Morrison K, Studer R, Ernst R, Haag F, Kausler K, Clozel M. Differential effects of selexipag and prostacyclin analogs in rat pulmonary artery. *J Pharmacol Exp Ther* 2012;343:547–55.
- [77] Woodward DF, Jones RL, Narumiya S. International union of basic and clinical pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. *Pharmacol Rev* 2011;63:471–538.
- [78] Kennedy I, Coleman RA, Humphrey PP, Levy GP, Lumley P. Studies on the characterisation of prostanoid receptors: a proposed classification. *Prostaglandins* 1982;24:667–89.
- [79] Lawrence RA, Jones RL, Wilson NH. Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum. *Br J Pharmacol* 1992;105:271–8.
- [80] Bennett A, Sanger GJ. Pinane thromboxane A₂ analogues are non-selective prostanoid antagonists in rat and human stomach muscle. *Br J Pharmacol* 1982;77:591–6.
- [81] Desai UA, Deo SK, Hyland KV, Poon M, Daunert S. Determination of prostacyclin in plasma through a bioluminescent immunoassay for 6-keto-prostaglandin F_{1α}: implication of dosage in patients with primary pulmonary hypertension. *Anal Chem* 2002;74:3892–8.
- [82] Norel X. Prostanoid receptors in the human vascular wall. *Sci World J* 2007;7:1359–74.
- [83] Foudi N, Kotelevets L, Louedec L, et al. Vasorelaxation induced by prostaglandin E₂ in human pulmonary vein: role of the EP₄ receptor subtype. *Br J Pharmacol* 2008;154:1631–9.
- [84] Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A₂. *Science* 2002;296:539–41.
- [85] Orié NN, Fry CH, Clapp LH. Evidence that inward rectifier K⁺ channels mediate relaxation by the PGI₂ receptor agonist cicaprost via a cyclic AMP-independent mechanism. *Cardiovasc Res* 2006;69:107–15.
- [86] Orié NN, Clapp LH. Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI₂ analogues in rat tail artery: evidence for G_{i/o} modulation via EP₃ receptors. *Eur J Pharmacol* 2011;654:258–65.
- [87] Ibrahim S, McCartney A, Markosyan N, Smyth EM. Heterodimerization with the prostacyclin receptor triggers thromboxane receptor relocation to lipid rafts. *Arterioscler Thromb Vasc Biol* 2013;33:60–6.
- [88] Hansmann G, Wagner RA, Schellong S, et al. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-γ activation. *Circulation* 2007;115:1275–84.
- [89] Abramovitz M, Adam M, Boie Y, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. *Biochim Biophys Acta* 2000;1483:285–93.
- [90] Clapp LH, Turcato S, Hall SJ, Baloch M. Evidence that Ca²⁺-activated K⁺ channels play a major role in mediating the vascular effects of iloprost and cicaprost. *Eur J Pharmacol* 1998;356:215–24.
- [91] Schermuly RT, Pullamsetti SS, Kwapiszewska G, et al. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. *Circulation* 2007;115:2331–9.
- [92] Mizuguchi S, Ohno T, Hattori Y, et al. Roles of prostaglandin E₂-EP1 receptor signaling in regulation of gastric motor activity and emptying. *Am J Physiol Gastrointest Liver Physiol* 2010;299:G1078–86.

- [93] Lai YJ, Pullamsetti SS, Dony E, et al. Role of the prostanoid EP₄ receptor in iloprost-mediated vasodilatation in pulmonary hypertension. *Am J Respir Crit Care Med* 2008;178:188–96.
- [94] Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. *Eur J Clin Pharmacol* 1986;30:61–8.
- [95] Aronoff DM, Peres CM, Serezani CH, et al. Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities. *J Immunol* 2007;178:1628–34.
- [96] Syed NI, Jones RL. Assessing the agonist profiles of the prostacyclin analogues treprostinil and naxaprostene, particularly their DP₁ activity. *Prostaglandins Leukot Essent Fatty Acids* 2015;95:19–29.
- [97] McSwain CS, Benza R, Shapiro S, et al. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion. *J Clin Pharmacol* 2008;48:19–25.
- [98] Gao Y, RajJU. Role of veins in regulation of pulmonary circulation. *Am J Physiol Lung Cell Mol Physiol* 2005;288:L213–26.
- [99] Norel X, Walch L, Labat C, Gascard JP, Dulmet E, Brink C. Prostanoid receptors involved in the relaxation of human bronchial preparations. *Br J Pharmacol* 1999;126:867–72.
- [100] Benyahia C, Gomez I, Kanyinda L, et al. PGE₂ receptor (EP₄) agonists: potent dilators of human bronchi and future asthma therapy. *Pulm Pharmacol Ther* 2012;25:115–8.
- [101] Petrucci G, De CR, Rutella S, et al. Prostaglandin E₂ differentially modulates human platelet function through the prostanoid EP₂ and EP₃ receptors. *J Pharmacol Exp Ther* 2011;336:391–402.
- [102] Hubertus K, Mischnik M, Timmer J, et al. Reciprocal regulation of human platelet function by endogenous prostanoids and through multiple prostanoid receptors. *Eur J Pharmacol* 2014;740:15–27.
- [103] Ali FY, Davidson SJ, Moraes LA, et al. Role of nuclear receptor signaling in platelets: antithrombotic effects of PPAR β . *FASEB J* 2006;20:326–8.
- [104] Huang S, Wettlaufer SH, Hogoabam C, Aronoff DM, Peters-Golden M. Prostaglandin E₂ inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling. *Am J Physiol Lung Cell Mol Physiol* 2007;292:L405–13.
- [105] Mori A, Ito S, Morioka M, Aso H, Kondo M, Sokabe M, Hasegawa Y. Effects of specific prostanoid EP receptor agonists on cell proliferation and intracellular Ca²⁺ concentrations in human airway smooth muscle cells. *Eur J Pharmacol* 2011;659:72–8.
- [106] Zhu S, Xue R, Zhao P, et al. Targeted disruption of the prostaglandin E₂ E-prostanoid 2 receptor exacerbates vascular neointimal formation in mice. *Arterioscler Thromb Vasc Biol* 2011;31:1739–47.
- [107] White ES, Atrasz RG, Dickie EG, et al. Prostaglandin E₂ inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity. *Am J Respir Cell Mol Biol* 2005;32:135–41.
- [108] Kolodick JE, Peters-Golden M, Larios J, Toews GB, Thannickal VJ, Moore BB. Prostaglandin E₂ inhibits fibroblast to myofibroblast transition via E prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. *Am J Respir Cell Mol Biol* 2003;29:537–44.
- [109] Moore BB, Ballinger MN, White ES, et al. Bleomycin-induced E prostanoid receptor changes alter fibroblast responses to prostaglandin E₂. *J Immunol* 2005;174:5644–9.
- [110] Kuwano K, Hashino A, Noda K, Kosugi K, Kuwabara K. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery. *J Pharmacol Exp Ther* 2008;326:691–9.
- [111] Morrison K, Ernst R, Hess P, Studer R, Clozel M. Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function. *J Pharmacol Exp Ther* 2010;335:249–55.
- [112] Jones RL, Woodward DF. Interaction of prostanoid EP₃ and TP receptors in guinea-pig isolated aorta: contractile self-synergism of 11-deoxy-16,16-dimethyl PGE₂. *Br J Pharmacol* 2011;162:521–31.
- [113] Zhao YJ, Wang J, Tod ML, Rubin LJ, Yuan XJ. Pulmonary vasoconstrictor effects of prostacyclin in rats: potential role of thromboxane receptors. *J Appl Physiol* 1996;81:2595–603.
- [114] Smith WL, DeWitt DL, Allen ML. Bimodal distribution of the prostaglandin I₂ synthase antigen in smooth muscle cells. *J Biol Chem* 1983;258:5922–6.
- [115] Lim H, Dey SK. A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. *Endocrinology* 2002;143:3207–10.
- [116] Katusic ZS, Santhanam AV, He T. Vascular effects of prostacyclin: does activation of PPAR δ play a role. *Trends Pharmacol Sci* 2012;33:559–64.
- [117] Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy- δ -12, 14-prostaglandin J₂ is a ligand for the adipocyte determination factor PPAR γ . *Cell* 1995;83:803–12.
- [118] Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. *Proc Natl Acad Sci U S A* 1997;94:4312–7.
- [119] Jin L, Lin S, Rong H, et al. Structural basis for iloprost as a dual peroxisome proliferator-activated receptor α/δ agonist. *J Biol Chem* 2011;286:31473–9.
- [120] Lin H, Lee JL, Hou HH, Chung CP, Hsu SP, Juan SH. Molecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells. *J Cell Physiol* 2008;214:434–41.
- [121] Pola R, Gaetani E, Flex A, et al. Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors. *J Mol Cell Cardiol* 2004;36:363–70.
- [122] Nemenoff R, Meyer AM, Hudish TM, et al. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor γ . *Cancer Prev Res* 2008;1:349–56.
- [123] He T, Lu T, d'Uscio LV, Lam CF, Lee HC, Katusic ZS. Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells. *Circ Res* 2008;103:80–8.
- [124] Huang JC, Wun WS, Goldsby JS, Egan K, FitzGerald GA, Wu KK. Prostacyclin receptor signaling and early embryo development in the mouse. *Hum Reprod* 2007;22:2851–6.
- [125] Falcetti E, Flavell DM, Staels B, Tinker A, Haworth SG, Clapp LH. IP receptor-dependent activation of PPAR γ by stable prostacyclin analogues. *Biochem Biophys Res Commun* 2007;360:821–7.
- [126] Lazennec G, Canaple L, Saugy D, Wahli W. Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. *Mol Endocrinol* 2000;14:1962–75.
- [127] Hamblin M, Chang L, Fan Y, Zhang J, Chen YE. PPARs and the cardiovascular system. *Antioxid Redox Signal* 2009;11:1415–52.
- [128] Wang J, Yang K, Xu L, et al. Sildenafil inhibits hypoxia-induced transient receptor potential canonical protein expression in pulmonary arterial smooth muscle via cGMP-PKG-PPAR γ axis. *Am J Respir Cell Mol Biol* 2013;49:231–40.
- [129] Turcato S, Clapp LH. The effects of the adenylyl cyclase inhibitor SQ22536 on iloprost-induced vasorelaxation and cAMP elevation in isolated guinea-pig aorta. *Br J Pharmacol* 1999;126:845–7.
- [130] Nisbet RE, Sutliff RL, Hart CM. The role of peroxisome proliferator-activated receptors in pulmonary vascular disease. *PPAR Res* 2007;2007:18797.
- [131] Li Y, Connolly M, Nagaraj C, et al. Peroxisome proliferator-activated receptor-beta/delta, the acute signaling factor in prostacyclin-induced pulmonary vasodilation. *Am J Respir Cell Mol Biol* 2012;46:372–9.
- [132] Liu G, Li X, Li Y, et al. PPAR δ agonist GW501516 inhibits PDGF-stimulated pulmonary arterial smooth muscle cell function related to pathological vascular remodeling. *Biomed Res Int* 2013;2013:903947.
- [133] Linz W, Wohlfart P, Baader M, et al. The peroxisome proliferator-activated receptor- α (PPAR- α) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats. *Acta Pharmacol Sin* 2009;30:935–46.
- [134] Jimenez R, Sanchez M, Zarzuelo MJ, et al. Endothelium-dependent vasodilator effects of peroxisome proliferator-activated receptor beta agonists via the phosphatidylinositol-3 kinase-Akt pathway. *J Pharmacol Exp Ther* 2010;332:554–61.
- [135] Nisbet RE, Bland JM, Kleinhenz DJ, et al. Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. *Am J Respir Cell Mol Biol* 2010;42:482–90.
- [136] Kozłowska H, Baranowska-Kuczko M, Schlicker E, Kozłowski M, Kloza M, Malinowska B. Relaxation of human pulmonary arteries by PPAR γ agonists. *Naunyn Schmiedeberg's Arch Pharmacol* 2013;386:445–53.
- [137] Green DE, Sutliff RL, Hart CM. Is peroxisome proliferator-activated receptor γ (PPAR γ) a therapeutic target for the treatment of pulmonary hypertension. *Pulm Circ* 2011;1:33–47.
- [138] Liu Y, Tian XY, Huang Y, Wang N. Rosiglitazone Attenuated endothelin-1-induced vasoconstriction of pulmonary arteries in the rat model of pulmonary arterial hypertension via differential regulation of ET-1 receptors. *PPAR Res* 2014;2014:374075.
- [139] Shen L, Ledwozyw A, Orie NN, et al. Differential action of beraprost stereoisomers, iloprost and treprostinil in modulating vascular tone in rat arteries: Role of PPAR β and prostanoid EP₃ receptors. *Am J Respir Crit Care Med* 2015 (in press).
- [140] Eddahibi S, Humbert M, Sediame S, et al. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. *Am J Respir Crit Care Med* 2000;162:1493–9.
- [141] Biscetti F, Gaetani E, Flex A, et al. Peroxisome proliferator-activated receptor alpha is crucial for iloprost-induced in vivo angiogenesis and vascular endothelial growth factor upregulation. *J Vasc Res* 2009;46:103–8.
- [142] Hoper MM, Voelkel NF, Bates TO, et al. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. *Am J Respir Cell Mol Biol* 1997;17:748–56.
- [143] Atsuta H, Uchiyama T, Kanai H, Iso T, Tanaka T, Suga T, Maeno T, Arai M, et al. Effects of a stable prostacyclin analogue beraprost sodium on VEGF and PAI-1 gene expression in vascular smooth muscle cells. *Int J Cardiol* 2009;132:411–8.
- [144] Piqueras L, Reynolds AR, Hodivala-Dilke KM, et al. Activation of PPAR β/δ induces endothelial cell proliferation and angiogenesis. *Arterioscler Thromb Vasc Biol* 2007;27:63–9.
- [145] Wang J, Ikeda R, Che XF, et al. VEGF expression is augmented by hypoxia-induced PGIS in human fibroblasts. *Int J Oncol* 2013;43:746–54.
- [146] He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. *J Biol Chem* 1999;274:25130–5.
- [147] Iwaguro H, Yamaguchi J, Kalka C, et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. *Circulation* 2002;105:732–8.

- [148] Smadja DM, Mauge L, Gaussem P, et al. Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension. *Angiogenesis* 2011;14:17–27.
- [149] Di SR, Barsotti MC, Melillo E, et al. The prostacyclin analogue iloprost increases circulating endothelial progenitor cells in patients with critical limb ischemia. *Thromb Haemost* 2008;100:871–7.
- [150] Murakami M, Watanabe M, Furukawa H, Nakahara H. The prostacyclin analogue beraprost sodium prevents occlusion of bypass grafts in patients with lower extremity arterial occlusive disease: a 20-year retrospective study. *Ann Vasc Surg* 2005;19:838–42.
- [151] Berman S, Quick R, Yoder P, Voigt S, Strootman D, Wade M. Treprostinil sodium (Remodulin), a prostacyclin analog, in the treatment of critical limb ischemia: open-label study. *Vascular* 2006;14:142–8.
- [152] Pope J. Treatment of systemic sclerosis. *Curr Opin Rheumatol* 1993;5:792–801.
- [153] Belch JJ, McLaren M, Lau CS, et al. Cicaprost, an orally active prostacyclin analogue: its effects on platelet aggregation and skin blood flow in normal volunteers. *Br J Clin Pharmacol* 1993;35:643–7.
- [154] Biscetti F, Gaetani E, Flex A, et al. Selective activation of peroxisome proliferator-activated receptor (PPAR) α and PPAR γ induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. *Diabetes* 2008;57:1394–404.
- [155] Ameshima S, Golpon H, Cool CD, et al. Peroxisome proliferator-activated receptor gamma (PPAR γ) expression is decreased in pulmonary hypertension and affects endothelial cell growth. *Circ Res* 2003;92:1162–9.
- [156] Guignabert C, Alvira CM, Alastalo TP, et al. Tie2-mediated loss of peroxisome proliferator-activated receptor- γ in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization. *Am J Physiol Lung Cell Mol Physiol* 2009;297:L1082–90.
- [157] Tsai MC, Chen L, Zhou J, et al. Shear stress induces synthetic-to-contractile phenotypic modulation in smooth muscle cells via peroxisome proliferator-activated receptor alpha/delta activations by prostacyclin released by sheared endothelial cells. *Circ Res* 2009;105:471–80.
- [158] Yang HM, Kim BK, Kim JY, et al. PPAR γ modulates vascular smooth muscle cell phenotype via a protein kinase G-dependent pathway and reduces neointimal hyperplasia after vascular injury. *Exp Mol Med* 2013;45:e65.
- [159] Ding M, Carrao AC, Wagner RJ, et al. Vascular smooth muscle cell-derived adiponectin: a paracrine regulator of contractile phenotype. *J Mol Cell Cardiol* 2012;52:474–84.
- [160] Wharton J, Davie N, Upton PD, Yacoub MH, Polak JM, Morrell NW. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. *Circulation* 2000;102:3130–6.
- [161] Ohtsubo H, Ichiki T, Miyazaki R, et al. Inducible cAMP early repressor inhibits growth of vascular smooth muscle cell. *Arterioscler Thromb Vasc Biol* 2007;27:1549–55.
- [162] Kothapalli D, Stewart SA, Smyth EM, Azonobi I, Pure E, Assoian RK. Prostacyclin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin a gene expression. *Mol Pharmacol* 2003;64:249–58.
- [163] Kadowaki M, Mizuno S, Demura Y, Ameshima S, Miyamori I, Ishizaki T. Effect of hypoxia and Beraprost sodium on human pulmonary arterial smooth muscle cell proliferation: the role of p27kip1. *Respir Res* 2007;8:77.
- [164] Sue YM, Chung CP, Lin H, et al. PPAR δ -mediated p21/p27 induction via increased CREB-binding protein nuclear translocation in beraprost-induced antiproliferation of murine aortic smooth muscle cells. *Am J Physiol Cell Physiol* 2009;297:C321–9.
- [165] Chen Y, Yang S, Yao W, et al. Prostacyclin analogue beraprost inhibits cardiac fibroblast proliferation depending on prostacyclin receptor activation through a TGF beta-Smad signal pathway. *PLOS ONE* 2014;9:e98483.
- [166] Clapp LH, Tennant BP. ATP-sensitive and inward rectifier K⁺ channels. In: Yuan JX, editor. *Ion channels in the pulmonary vasculature*. Boca Raton: Taylor & Francis; 2005. p. 257–86.
- [167] Olschewski A, Papp R, Nagaraj C, Olschewski H. Ion channels and transporters as therapeutic targets in the pulmonary circulation. *Pharmacol Ther* 2014;144:349–68.
- [168] Jabr RI, Wilson AJ, Riddervold MH, Jenkins AH, Perrino BA, Clapp LH. Nuclear translocation of calcineurin A β but not calcineurin A α by platelet-derived growth factor in rat aortic smooth muscle. *Am J Physiol* 2007;292:C2213–25.
- [169] Bonnet S, Rochefort G, Sutendra G, et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. *Proc Natl Acad Sci U S A* 2007;104:11418–23.
- [170] Morimoto T, Hasegawa K, Wada H, et al. Calcineurin-GATA4 pathway is involved in beta-adrenergic agonist-responsive endothelin-1 transcription in cardiac myocytes. *J Biol Chem* 2001;276:34983–9.
- [171] Davie N, Haleen SJ, Upton PD, et al. ET_A and ET_B receptors modulate the proliferation of human pulmonary artery smooth muscle cells. *Am J Respir Crit Care Med* 2002;165:398–405.
- [172] Rehberger P, Beckheinnrich-Mrowka P, Hausteiner UF, Sticherling M. Prostacyclin analogue iloprost influences endothelial cell-associated soluble adhesion molecules and growth factors in patients with systemic sclerosis: a time course study of serum concentrations. *Acta Derm Venereol* 2009;89:245–9.
- [173] Ali FY, Egan K, FitzGerald GA, et al. Role of prostacyclin versus peroxisome proliferator-activated receptor β receptors in prostacyclin sensing by lung fibroblasts. *Am J Respir Cell Mol Biol* 2006;34:242–6.
- [174] Han S, Ritzenthaler JD, Sun X, Zheng Y, Roman J. Activation of peroxisome proliferator-activated receptor β/δ induces lung cancer growth via peroxisome proliferator-activated receptor coactivator gamma-1alpha. *Am J Respir Cell Mol Biol* 2009;40:325–31.
- [175] Harrington LS, Moreno L, Reed A, et al. The PPAR β/δ agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension. *PLoS ONE* 2010;5:e9526.
- [176] Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. *N Engl J Med* 1992;327:70–5.
- [177] Adatia I, Barrow SE, Stratton PD, Miall-Allen VM, Ritter JM, Haworth SG. Thromboxane A₂ and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. *Circulation* 1993;88:2117–22.
- [178] Fukushima H, Kosaki K, Sato R, et al. Mechanisms underlying early development of pulmonary vascular obstructive disease in Down syndrome: an imbalance in biosynthesis of thromboxane A₂ and prostacyclin. *Am J Med Genet A* 2010;152A:1919–24.
- [179] Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. *Am J Respir Crit Care Med* 1999;159:1925–32.
- [180] Mahajan CN, Afolayan AJ, Eis A, Teng RJ, Konduri GG. Altered prostanoid metabolism contributes to impaired angiogenesis in persistent pulmonary hypertension in a fetal lamb model. *Pediatr Res* 2015;77:455–62.
- [181] Geraci MW, Gao B, Shepherd DC, et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. *J Clin Invest* 1999;103:1509–15.
- [182] Nagaya N, Yokoyama C, Kyotani S, et al. Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. *Circulation* 2000;102:2005–10.
- [183] Zhou W, Dowell DR, Geraci MW, et al. PGI synthase overexpression protects against bleomycin-induced mortality and is associated with increased Nqo 1 expression. *Am J Physiol Lung Cell Mol Physiol* 2011;301:L615–22.
- [184] Stearman RS, Cornelius AR, Lu X, et al. Functional prostacyclin synthase promoter polymorphisms. Impact in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2014;189:1110–20.
- [185] Ibrahim S, Tetrushvily M, Frey AJ, et al. Dominant negative actions of human prostacyclin receptor variant through dimerization: implications for cardiovascular disease. *Arterioscler Thromb Vasc Biol* 2010;30:1802–9.
- [186] Wilkins MR, Wharton J, Grimminger F, Ghofrani HA. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. *Eur Respir J* 2008;32:198–209.
- [187] Begum N, Hockman S, Manganiello VC. Phosphodiesterase 3A (PDE3A) deletion suppresses proliferation of cultured murine vascular smooth muscle cells (VSMCs) via inhibition of mitogen-activated protein kinase (MAPK) signaling and alterations in critical cell cycle regulatory proteins. *J Biol Chem* 2011;286:26238–49.
- [188] Bowles EA, Moody GN, Yeragunta Y, Stephenson AH, Ellsworth ML, Sprague RS. Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension. *Exp Biol Med* 2015;240:121–7.
- [189] Laflamme M, Perrault LP, Carrier M, Elmi-Sarabi M, Fortier A, Denault AY. Preliminary experience with combined inhaled milrinone and prostacyclin in cardiac surgical patients with pulmonary hypertension. *J Cardiothorac Vasc Anesth* 2015;29:38–45.
- [190] Resnick KA, Gordon IL. Effects of cilostazol on arterial wound healing: a retrospective analysis. *Ann Vasc Surg* 2014;28:1513–21.
- [191] Tian X, Vroom C, Ghofrani HA, et al. Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling. *PLoS ONE* 2011;6:e18136.
- [192] Bubb KJ, Trinder SL, Baliga RS, et al. Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension. *Circulation* 2014.
- [193] Smyth EM, Li WH, FitzGerald GA. Phosphorylation of the prostacyclin receptor during homologous desensitization. A critical role for protein kinase c. *J Biol Chem* 1998;273:23258–66.
- [194] Sobolewski A, Jourdan KB, Upton PD, Long L, Morrell NW. Mechanism of cicaprost-induced desensitization in rat pulmonary artery smooth muscle cells involves a PKA-mediated inhibition of adenylyl cyclase. *Am J Physiol Lung Cell Mol Physiol* 2004;287:L352–9.
- [195] Walsh MT, Foley JF, Kinsella BT. The α , but not the β , isoform of the human thromboxane A₂ receptor is a target for prostacyclin-mediated desensitization. *J Biol Chem* 2000;275:20412–23.
- [196] Kowal-Bielecka O, Kowal K, Distler O, et al. Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators. *Arthritis Rheum* 2005;52:3783–91.
- [197] Penn RB, Pascual RM, Kim YM, et al. Arrestin specificity for G protein-coupled receptors in human airway smooth muscle. *J Biol Chem* 2001;276:32648–56.
- [198] Lakshmi SP, Reddy AT, Zhang Y, et al. Down-regulated peroxisome proliferator-activated receptor γ (PPAR γ) in lung epithelial cells promotes a PPAR γ agonist-reversible proinflammatory phenotype in chronic obstructive pulmonary disease (COPD). *J Biol Chem* 2014;289:6383–93.
- [199] Lu X, Bijli KM, Ramirez A, Murphy TC, Kleinhenz J, Hart CM. Hypoxia downregulates PPAR γ via an ERK1/2-NF-kappaB-Nox4-dependent mechanism in human pulmonary artery smooth muscle cells. *Free Radic Biol Med* 2013;63:151–60.

- [200] Hansmann G, de Jesus Perez V, Alastalo TP, et al. An antiproliferative BMP-2/PPAR γ /apoE axis in human and murine SMCs and its role in pulmonary hypertension. *J Clin Invest* 2008;118:1846–57.
- [201] Benayoun L, Letuve S, Druilhe A, et al. Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling. *Am J Respir Crit Care Med* 2001;164:1487–94.
- [202] Czimmerer Z, Varga T, Poliska S, Nemet I, Szanto A, Nagy L. Identification of novel markers of alternative activation and potential endogenous PPAR γ ligand production mechanisms in human IL-4 stimulated differentiating macrophages. *Immunobiology* 2012;217:1301–14.
- [203] Li C, Mpollo MS, Gonsalves CS, Tahara SM, Malik P, Kalra VK. Peroxisome proliferator-activated receptor-alpha-mediated transcription of miR-199a2 attenuates endothelin-1 expression via hypoxia-inducible factor-1alpha. *J Biol Chem* 2014;289:36031–47.
- [204] Duan SZ, Usher MG, Mortensen RM. PPARs: the vasculature, inflammation and hypertension. *Curr Opin Nephrol Hypertens* 2009;18:128–33.
- [205] Yang J, Davies RJ, Southwood M, et al. Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension. *Circ Res* 2008;102:1212–21.
- [206] Chida A, Shintani M, Yagi H, et al. Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers. *Am J Cardiol* 2012;110:586–93.
- [207] Kojonazarov B, Luitel H, Sydykov A, et al. The peroxisome proliferator-activated receptor β/δ agonist GW0742 has direct protective effects on right heart hypertrophy. *Pulm Circ* 2013;3:926–35.
- [208] van Albada ME, Berger RM, Niggebrugge M, van VR, Cromme-Dijkhuis AH, Schoemaker RG. Prostacyclin therapy increases right ventricular capillarisation in a model for flow-associated pulmonary hypertension. *Eur J Pharmacol* 2006;549:107–16.
- [209] Hall S, Brogan P, Haworth SG, Klein N. Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in children. *Thorax* 2009;64:778–83.
- [210] Klings ES, Anton BD, Rosenman D, et al. Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression. *Am J Hematol* 2008;83:547–53.
- [211] Sakamaki F, Kyotani S, Nagaya N, et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. *Circulation* 2000;102:2720–5.
- [212] Goya K, Otsuki M, Xu X, Kasayama S. Effects of the prostaglandin I₂ analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus. *Metabolism* 2003;52:192–8.
- [213] Riva CM, Morganroth ML, Ljungman AG, et al. Iloprost inhibits neutrophil-induced lung injury and neutrophil adherence to endothelial monolayers. *Am J Respir Cell Mol Biol* 1990;3:301–9.
- [214] Konya V, Sturm EM, Schratl P, et al. Endothelium-derived prostaglandin I₂ controls the migration of eosinophils. *J Allergy Clin Immunol* 2010;125:1105–13.
- [215] Birukova AA, Wu T, Tian Y, et al. Iloprost improves endothelial barrier function in lipopolysaccharide-induced lung injury. *Eur Respir J* 2013;41:165–76.
- [216] Braun M, Pietsch P, Zepp A, Schror K, Baumann G, Felix SB. Regulation of tumor necrosis factor α - and interleukin-1- β -induced induced adhesion molecule expression in human vascular smooth muscle cells by cAMP. *Arterioscler Thromb Vasc Biol* 1997;17:2568–75.
- [217] Raychaudhuri B, Malur A, Bonfield TL, et al. The prostacyclin analogue treprostinil blocks NF κ B nuclear translocation in human alveolar macrophages. *J Biol Chem* 2002;277:33344–8.
- [218] Tsai MK, Hsieh CC, Kuo HF, et al. Effect of prostaglandin I analogs on monocyte chemoattractant protein-1 in human monocyte and macrophage. *Clin Exp Med* 2014. <http://dx.doi.org/10.1007/s10238-014-0304-7>.
- [219] Wang WL, Kuo CH, Chu YT, et al. Prostaglandin I₂ analogues suppress TNF- α expression in human monocytes via mitogen-activated protein kinase pathway. *Inflamm Res* 2011;60:655–63.
- [220] Zhou W, Hashimoto K, Goleniewska K, et al. Prostaglandin I₂ analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. *J Immunol* 2007;178:702–10.
- [221] Zhou W, Blackwell TS, Goleniewska K, et al. Prostaglandin I₂ analogs inhibit Th1 and Th2 effector cytokine production by CD4T cells. *J Leukoc Biol* 2007;81:809–17.
- [222] Di RM, Pieragalli D, Meini S, et al. Iloprost treatment reduces TNF-alpha production and TNF-RII expression in critical limb ischemia patients without affecting IL6. *Prostaglandins Leukot Essent Fatty Acids* 2005;73:405–10.
- [223] Katsushi H, Kazufumi N, Hideki F, et al. Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension. *Circ J* 2004;68:227–31.
- [224] Kiriya M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. *Br J Pharmacol* 1997;122:217–24.
- [225] Blair IA, MacDermot J. The binding of [³H]-prostacyclin to membranes of a neuronal somatic hybrid. *Br J Pharmacol* 1981;72:435–41.
- [226] Shepherd GL, Lewis PJ, Blair IA, de MC, MacDermot J. Epoprostenol (prostacyclin, PGI₂) binding and activation of adenylate cyclase in platelets of diabetic and control subjects. *Br J Clin Pharmacol* 1983;15:77–81.
- [227] Davis TL, Sharif NA. Pharmacological characterization of [³H]-prostaglandin E₂ binding to the cloned human EP₄ prostanoid receptor. *Br J Pharmacol* 2000;130:1919–26.